

Co-host



China Center for Food and Drug International Exchange (CCFDIE)



### 2022 DIA China Annual Meeting

### PROGRAM CO-CHAIRMEN



## Lili CAO

Co-chair of 2022 DIA China Annual Meeting Deputy Director, China International Food and Drug Exchange Center (CCFDIE), NMPA

### • PROGRAM STEERING COMMITTEE



**Zili LI, MD, MPH** Vice President, Head of Asia Pacific R&D, Janssen Research & Development



Feng CHEN, PhD, Professor Professor, School of Public Health, Nanjing Medical University



Wendy YAN Co-chair of 2022 DIA China Annual Meeting VP and Head of RA, BeiGene



Shun LU, MD, PhD Director, Shanghai Lung Cancer Center, Shanghai Jiaotong University, China Chair, Advisory Council of China, DIA

Head of Medical Office R&D, I-Mab Biopharma



Zaiqi WANG, PhD CEO, InxMed

Isaac MENG



Ning XU, MD Executive Vice President, Head of Clinical Development, Zai Lab



Mengjuan LI HR Head, Asia Pacific R&D and Innovation, Johnson & Johnson



**Tongyan WANG, PhD** Senior Vice President and Managing Director, DIA China

### 2022 DIA China Annual Meeting

### ● 国际顾问委员会 | INTERNATIONAL ADVISORY COMMITTEE



Theresa MULLIN, PhD 美国FDA药品审评和研究中心(CDER)副主任 战略事务负责人 ICH管理委员会主席 Associate Director for Strategic Initiatives FDA Center for Drug Evaluation and Research



### 苏岭 博士 | Ling SU, PhD

樊代明 | Daiming FAN

Fellow of DIA 沈阳药科大学教授;礼来亚洲基金风险合伙人 Professor in Shenyang Pharmaceutical University and a Venture Partner with Lilly Asia Ventures

Council Member of the World Gastroenterology



**Dr. Sabine HAUBENREISSER** 欧洲药品管理局 (EMA) 利益相关者和沟通部主任科学行政官 Principal Scientific Administrator Stakeholders and Communication European Medicines Agency



Nobumasa Nakashima 博士 | PhD 日本PMDA国际项目执行副主任 Associate Executive Director for International Programs Pharmaceuticals and Medical Devices Agency(PMDA)



Peter Honig, MD, MPH DIA全球董事会成员, 独立顾问 前辉瑞高级副总裁 Independent Advisor and Board Member and Former SVP Pfizer

教授,中国抗癌协会会长,中国工程院院士,美国医学科学院外籍院士

Professor, President of the Chinese Anti-Cancer Association,

President of Asian Pacific Association of Gastroenterology,



**谭凌实 博士 | Lingshi TAN, PhD** 缔脉生物医药科技(上海)有限公司 董事长兼首席执行官 Chairman and CEO of Caidya



**江宁军 医学博士 | Frank N. JIANG, PhD** 基石药业高级顾问 Senior Consultant, Cstone Pharmaceuticals



Sandra A. Milligan, PhD 默克研究所高级副总裁 兼法规事务及药品安全负责人 Executive Vice President and Head of Research and Development, Organon & Co., Merck



Ken GETZ Tufts药物发展研究中心资助研究项目部主任

Professor and the Director of the Center for the Study of Drug Development, Tufts University School of Medicine

### 2022 DIA China Annual Meeting | Program Committee

### **Regulatory Science**



Wendy YAN Senior Vice President, Head of Regulatory Affairs, BeiGene (Beijing) Co., Ltd.



**Jessica CHANG** Vice President, Drug Regulatory Policy, Tigermed



Irene DENG Regulatory Affairs Head, Sanofi



**Angela YAN** President, R&D and Operations China & Asia, Kira Pharma



**Xiaoyuan CHEN, MD, PhD** Director, GCP Officer, Beijing Tsinghua Changgung Hospital



**Joyce LIU** China Regulatory Affairs Head, Takeda

### **Clinical Drug Development**



Shun LU, MD, PhD Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital, Shanghai Jiaotong University

**Jing HE, MD, PhD** SVP, Head of China R&D Global Oncology R&D, Astrazeneca

Xingli WANG, MD, PhD ACC Member, DIA



**Zhaohua CHEN** Head of Global Climical Data Services Pfizer China R&D Center

Jessie ZOU, MD, PhD President, Global R&D, Junshi Biosciences







Gailing LI, PhD Chief Scientist Officer, Certara

## Patient Focused Clinical Operations and Quality Management



Ning XU, MD, PhD Executive Vice President, Head of Clinical Development and Regulatory Affairs, Zai Lab



Yang LIN Director of Phase I Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University



Jing ZHANG, PhD Professor of Clinical Pharmacology, Deputy Director, Institute of Antibiotics, Huashan Hospital, Fudan University



Liping ZHOU Senior Director, QA, MSD R&D (China) Co., Ltd



**Shuting LI** Vice president of Jimin Cancer Hospital affiliated to Anhui Medical University



Veronica XIA Vice President, China GM, Labcorp



Amy JIANG Head of Quality Office, Harbour Biomed

### 2022 DIA China Annual Meeting | Program Committee

### **Clinical Needs and Trial Platform**



### Ning LI, MD, PhD

Chief Physician, Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences



#### Jie LI Chief Physician, Department of Digestive Oncology, Peking University Cancer Hospital Chairman of Ethics Committee of Peking University Cancer Hospital



**Jessica LIU** Head of M&A Department, Tigermed

### **Data Science**



Daniel LIU, PhD Chief Science Officer Beijing Clinical Service Center



**Hualong SUN, PhD** General Manager Meta Clinical Technology Co. Ltd



### Anita SHEN

Executive Director, Head of Clinical Data Monitoring and Management (DMM),, Pfizer

### **Biostatistics**








Professor, Dean, School of Public Health

Feng CHEN, PhD

Wei ZHANG, PhD







Michael LEE, PhD Vice President, Head of Biometrics Harbour BioMed

VP, Regional Head of Biometrics and Data

Ingelheim Shanghai Pharmaceuticals Co., Ltd.

Management, Asia/MENA, Boehringer

#### Lihong HUANG, PhD Department of Biostatis

Department of Biostatistics Zhongshan Hospital, Fudan University

## 9

Tony GUO, PhD Global Head of Statistics and Data Science, VP, BeiGene

### СМС



Steven HU, PhD Chief Technical Officer, Everest Medicine



Lily XIONG Executive Director, CMC, BeiGene



Xiaoping CAO, PhD SVP, Head of Technology Operations JW Therapeutics



Na XU RA Director, 3DMed

### **Medical Writing and Publication**



Nan WANG, PhD Vice President, Head of Medical Writing Bayer Pharmaceuticals

### 2022 DIA China Annual Meeting | Program Committee

### PV & Drug Safety



Yuan MENG Head of Medical Office R&D, I-Mab Biopharma



**Conny MO** Founder, Medical Safety Advisor, Beijing XAJK Medical Technology, Co., Ltd.



Howe LI, MD, PhD Chairman and CEO, Deltamed Co. Ltd



**Xiaojing ZHAN** Vice President, Drug Safety, Junshi



#### Vera LIANG

Director and Global Safety Risk Lead, Safety Surveillance and Risk Management Pfizer (China) R&D Co., Ltd.



#### Zheng JIAO

Director of Pharmacy Department, Deputy Director of GCP Center, Chest Hospital Affiliated to Shanghai Jiaotong University

### **Non-clinical & Animal Test**





## Yi JIN, PhD

VP and Head of Program Management and Regulatory Affairs, WuXi Appec Suzhou

## E



### Xiantang LI, PhD Senior Director, Non-clinical Drug Safety, Pfizer

### **Translational Medicine**



Xinying SU, MD, PhD Senior Director, Translational Medicine and Diagnostic Lead, Development China, Pfizer

## Yi Z

Yi ZHENG, PhD Head of Translational Science Center, JnJ

### **Medical Affairs**



Haidong CHI, MD, PhD CMO, Lilly China

### **BD** Roadshow



Liqun WANG, PhD Founder, Chairman and Chief Executive Officer NeuKio



**Yi LIU** Chief Medical Officer and Senior Vice President, Caidya Biopharmaceutical Co., Ltd



### 2022 DIA China Annual Meeting

### POSTER REVIEW COMMITTEE (评委姓名按首字母排序)



Irene DENG Regulatory Affairs Head, Sanofi



Howe LI, MD, PhD Chairman and CEO, Deltamed Co. Ltd



Daniel LIU, PhD Chief Science Officer Beijing Clinical Service Center



Rong SHAO Director of Research Institute of Drug Regulatory Science China Pharmaceutical University



Yue YANG Professor, School of Pharmacy Tsinghua University



**Chen YAO, PhD** Director, Department of Medical Statistics, Peking University First Hospital 2022 DIA China Annual Meeting



The ICH day and 15 themes designed to advance health care outcomes through innovation and regulatory reforms





**Educational Workshop** 



Openning





**Regulatory Science** 



Clinical Drug Development





Patient Focused Clinical **Operations and Quality** Management



**Clinical Needs and Trial Platform** 



Data Science

**Biostatistics** 



PV & Drug Safety





**Translational Medicine** 



Non-clinical & Animal Test



Publication



**Development Forum** 



Professional Development White Paper Showcase



Community E&E

# Medical Writing and



Hot Topics

ICH Day	ІСН
Educational Workshop	$\overline{}$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	

Hot Topics

## Thursday | December 8<sup>th</sup> | ICH DAY



Since its inception in 1990, founded by the drug regulatory agencies of the US, EU, and Japan along with industry associations, to its reform and establishment of the non-profit, non-governmental legal entity under Swiss law in 2015, International Council for Harmonzation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has successfully attracted regulators around the world to join and ensure greater coordination among the participating regulatory agencies. The purpose of ICH is to promote public health through international harmonization of technical requirements that contributes to the timely introduction of new medicines and continued availability of the approved medicines to patients, to the prevention of unnecessary duplication of clinical trials in humans, to the development, registration and manufacturing of safe, effective, and high quality medicines in an efficient and cost-effective manner, and to the minimization of the use of animal testing without compromising safety and effectiveness.

2022 is the 5th year since NMPA, China joined ICH Management Committee, to promote the ICH's global development strategy, DIA China 2022 ICH Day will invite the speaker from ICH core member countries to forward look the ICH's Further Initiatives from global perspectives, impact and updates for the new ICH Patient Focused Drug Development Guideline, as well ICH's Key Achievements and Implementation in China.

ICH Q series, S series, E9R1, E6R3, E8R1 and M4QR2 will be also covered.

	Plenary
	PROGRAM CO-CHAIRS NMPA Co-chair Invited
	<b>Zili LI, MD, MPH</b> Chair, DIA Advisory Council of China Vice President and Head of Asia Pacific R&D, Janssen Pharmaceutical Company
8:30-8:35	Welcome
8:35-8:50	Views of Different Stakeholders on How ICH Has Contributed to Better Health and ICH's Future Capacity Building Directions in the Nex 5-10 Years
	<b>Theresa MULLIN, PhD</b> Associate Director for Strategic Initiatives, FDA Center for Drug Evaluation and Research Chair, ICH Management Committee
8:50-9:00	PMDA Guidance on Patient Participation-PMDA's Consideration
	<b>Junko SATO, PhD</b> Director, Office of International ProgramsPharmaceuticals and Medical Devices Agency (PMDA) A Member of the ICH Patient Centricity Working Group
9:00-9:30	ICH's Key Achievements and Implementation in China
	China ICH Representative Invited
9:30-10:00	Tea Break

ICH Day	ICH	Th
Educational Worksho	op 🕣	Works
Opening Plenary		ICH I
Global Regulatory Townhall		PROG China
China Regulatory Special Session		<b>Meng</b> Roche
Regulatory Science		Worki - Why - Wha - Key
Drug Clinical Development		- Worl
Patient Centered Clinical Op and Quality Management	erations	Lawre Direct U.S. Fo
Clinical Needs and Trial Platform		<b>China</b> - Back - CDE'
Data Science		- CDE' China
Biostatistics		Indust - Real- - Indu
PV & Drug Safety		Rodri
СМС		Global Panel
Translational Medici	ines	Invited Quan CMC F
Non-clinical & Animal T	Test	<b>Peter</b> Lead E
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum	ר	

Hot Topics

## Thursday | December 8<sup>th</sup> | ICH DAY



#### Workshop 1 | 10:00-12:00 ICH M4Q Workshop - Informational Session

#### PROGRAM CO-CHAIRS

China CDE Co-chair Invited

Meng YANG, PhD Roche

#### Working group's expectations and updates on ICH M4Q revision. An overview introduction on the guidance revision, which could include:

- Why to revise the guideline
- What goals to achieve
- Key points/issues/considerations
- Work plan and timelines

#### Lawrence YU, PhD

Director, Office of New Drug Products, OPQ/CDER U.S. Food and Drug Administration

#### China CDE's Expectations and Update on ICH M4Q Revision

- Background information
- CDE's considerations and expectations to the revision
- CDE's suggestions to local companies on the M4Q implementation

China CDE Speaker Invited

#### ndustry Perspective and Expectations on ICH M4Q Revision

- Real-world challenges of M4Q implementation and harmonization
- Industry's expectations

#### Rodrigo PALACIOS

Global Regulatory Policy Lead for Digital Infrastructure, Roche

#### anel Discussion

Invited Panelists Quan YANG CMC Registration Head, Novartis

Peter QIU Lead External Advocacy China, Roche

ICH	Day



ICH

 $( \mathbf{i} )$ 

Î

Ì

1000

F

Opening Plenary

Global Regulatory Townhall

China Regulatory Special Session

**Regulatory Science** 

Drug Clinical Development

Patient Centered Clinical Operations

Clinical Needs and Trial Platform

Data Science

Biostatistics

PV & Drug Safety

СМС

Translational Medicines

Non-clinical & Animal Test

Medical Writing and Publication

Pediatric Drug Development Forum

Hot Topics

## Thursday | December 8<sup>th</sup> | ICH DAY



Workshop 2 | 10:00-12:00 E8R1

PROGRAM CO-CHAIRS CDE Co-chair Invited

Tony GUO, PhD Global Head of Statistics and Data Science, VP, BeiGene

ICH E8R1 Guideline's Implementation in China CDE Speaker Invited

ICH E8: Connection and Case Study with ICH E6 & E17 William WANG, PhD Executive Director, Clinical Safety Statistics, Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories

Panel Discussion Invited Panelists Angela YAN DIA ACC Member

Jiaojiao YU Senior Project Manager, Tigermed

Yi LIU Chief Medical Officer and Senior Vice President, Caidya Biopharmaceutical Co., Ltd

Hao WANG Head of Clinical Operations, Roche China

ICH Day		ІСН	
Educatior	al Workshop	0	
Opening I	Plenary		
Global Re Townhall	gulatory		
China Re Special S			
Regulato	ry Science		
Drug Clin Developn	ical nent		
Patient Cente and Quality M	ered Clinical Operations 1anagement		
Clinical N Trial Platf	eeds and orm		
Data Scie	nce		
Biostatist	ics		
PV & Drug	y Safety		
СМС			
Translatio	onal Medicines		
Non-clinica	al & Animal Test		
Medical V Publicatio	Vriting and on	Ê	
Pediatric Developn	Drug nent Forum	X	
		SIMULA	

## Thursday | December 8<sup>th</sup> | ICH DAY



Workshop 3 | 13:30-17:20 E9(R1): Implementation and Consideration of ICH E9(R1) Estimand Framework

#### PROGRAM CO-CHAIRS

**Feng CHEN, PhD** Professor of Biostatistics, Nanjing Medical University Chair of China Clinical Trial Statistics (CCTS) Working Group

Tao WANG, PhD Hengrui Pharma

In China, we expect to implement the ICH-E9(R1) Estimand framework in 2022. However, there are still a large number of clinical trial scientists do not clearly understand the purpose, contents and specific applications of this new framework. Therefore, the DIA statistical community has built up a working group of ESTIMAND BLUEBOOK to collect and sort out specific cases in different therapeutic areas and summarize some special considerations, hoping to launch the BlueBook for reference later this year. This training will provide an overview of the ICH-E9(R1) guidelines as well as case studies from different therapeutic areas to help you better understand and apply the Estimand Framework.

#### Introduction of ICH-E9(R1) and Estimand Framework Feng CHEN, PhD

Professor of Biostatistics, Nanjing Medical University Chair of China Clinical Trial Statistics (CCTS) Working Group

Scientific Interpretation and Findings of Implementation of E9(R1) in China CDE Speaker Invited

#### Experience Sharing of Implementation of E9(R1) - from Statistics Perspective CDE Speaker Invited

Overview of Trial Design and Statistical Analysis Plan with Estimand Framework Jiawei WEI, PhD Novartis

Sensitivity Analysis and the Identification of Intercurrent Events Jeannie QIU, PhD Head of Biometrics and Data Science, FosunPharma Global R&D Center

#### Estimands in Oncology **Zhiyue HUANG, PhD** Roche

Estimands in Non-Oncology Na HU Senior Principal Statistician, Boehringer-Ingelheim

Estimands in Vaccine **Zhiwei JIANG, PhD** KeyTech

Panel Discussion

Hot Topics

ICH Day	ІСН
Educational Workshop	•
Opening Plenary	
Global Regulatory Townhall	$( \mathbf{G} )$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	

Hot Topics

## Thursday | December 8<sup>th</sup> | ICH DAY

Workshop 4 | 10:00-15:00

ICH E6 - Informational Session

#### PROGRAM CHAIR

Sally ZHANG Head, Quality Assurance, AstraZeneca ICH E6R3 Global Expert Working Group (EWG)

ICH E6 is being revised with new content and trends. It is critical that essential progresses are continually communicated and understood, by the R&D industry in China and its stakeholders, to facilitate the readiness of their future implementation.

As such, this session would invite E6 WG professional representatives from CHINA, EU, US to share the latest updates of ICH E6. Through the sharing of guideline updates and industry advancing practice on Patient Engagement and Quality by Design, invited stakeholder representative would share their insights of the values in applying Patient Engagement and Quality by design in clinical research at the Panel session.

10:00-10:10	Opening		
10:10-10:30	ICH E6 R3 Global Revision Progress Update		
	China CDE Speaker Invited		
10:30-11:20	The Framework of "Patient Centricity" in New Drug Development		
	<b>Sally ZHANG</b> Head, Quality Assurance, AstraZeneca ICH E6R3 Global Expert Working Group (EWG)		
	Weiyi ZHENG VP, Head of Clinical Operations, R&D China, AstraZeneca		
11:20-11:35	The Practice of "Public and Patient Participation" System in UK		
	<b>Ping JI, PhD</b> Professor, Associate Director, Peking University Clinical Research Institute (Shenzhen)		
11:35-11:50	Case Sharing- Patient Engagement Practice in Japan		
	<b>Kazuyuki SUZUKI</b> Team Lead, Patient Engagement, Novartis Japan		
11:50-12:00	Wrap Up of Morning Session		
	<b>Sally ZHANG</b> Head of R&D Quality Assurance APAC, AstraZeneca ICH E6 R3 Global Expert Working Group		
12:10-13:30	Lunch	2022 DIA China Annual Masting	-
· · · · · · · · · · · · · · · · · · ·		2022 DIA China Annual Meeting	-



ICH Day	ІСН
Educational Workshop	<b>(</b> )
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	Ø
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

## Thursday | December 8<sup>th</sup> | ICH DAY



13:30–14:50 Panel Discussion:

Panel Discussion: Patient Centricity - Global Landscape and Insight for Implementation in China based on ICH E6 R3

#### CO-MODERATORS

Sally ZHANG Head, Quality Assurance, AstraZeneca ICH E6R3 Global Expert Working Group (EWG)

CDE Moderator Invited

#### INVITED PANELISTS Ning LI, MD, PhD Chief Physician, Vice President of Cancer Hospital of Chinese Academy of Medical Sciences

Haiyan LI Director of Drug Clinical Trial Institution, Chief Physician of Cardiovascular Medicine, Peking University Third Hospital

Yifeng SHEN Chief Physician, Director of Drug Clinical Trial Institution, Shanghai Mental Health Center

Jing HE, MD, PhD SVP, Head of China R&D Global Oncology R&D, Astrazeneca

Jason YANG, PhD Chief Executive Officer, CStone ICH E6 R3 Global Expert Working Group

Julia WANG Executive Director, Clinical Operations, Eli Lilly

Hannah CHEN GCP Consultant, Beijing XiaoTongMingDa Technology Ltd. Founder, China QA Forum (CQAF)

14:50–15:00 Closing

CH Day	inurse	day   December 8 <sup>th</sup>   ICH DAY	ССН
ducational Workshop	Workshop 5		10.
Dpening Plenary	PROGRAM CO-	CHAIRS	
ownhall	CDE Co-chair In Xiaoping CAC		
China Regulatory	SVP Head of Te	chnology Operations, JW Therapeutics	
Special Session	000000000000000000000000000000000000000	D Officer, Everest Medicine	
Regulatory Science			
	10:00-10:30	Global Regulatory Harmonization for CMC Control Strategy	
Development 🛛 🔀		Greg RULLO Senior Director, Regulatory Affairs - CMC, AZ R&D	
atient Centered Clinical Operations	10:30-10:50	Q12 Guideline Implementation in China	
Clinical Needs and		CDE Speaker Invited	
Clinical Needs and	10:50-11:10	Progress on the Global Adoption and Implementation of ICH Q12	
Data Science		Andrew CHANG, PhD Vice President, Quality and Regulatory Compliance, Quality, Novo Nordisk	
Biostatistics	11:10-11:30	Q12 Implementation case studies - Small Molecules	
PV & Drug Safety		Connie LANGER Director, Pfizer	
	11:30-11:50	Q12 Implementation case studies - Large Molecules	
смс		Monica Perea-Velez, PhD CMC Advocacy and Policy Director Development GRA CMC Excellence, GSK	
ranslational Medicines	11:50-12:10	Analytical Procedure Life Cycle and Q12 & Q14	
Ion-clinical & Animal Test		<b>Dr. Amanda Mesquita GUIRALDELLI</b> Scientific Affairs Manager, USP	
1edical Writing and	12:10-13:30	Lunch	
Publication	13:30-13:50	ICH Q13 Implementation in China	
Pediatric Drug Development Forum		CDE Speaker Invited	

ICH Day	ІСН
Educational Workshop	•
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

## Thursday | December 8<sup>th</sup> | ICH DAY

13:50-14:10	Q13 Presentation from MNC Perspective
	Speaker Invited
14:10-14:30	Q13 Presentation from Local Company Perspective
	Huangfei DENG Vice President, Technology, Triastek
14:30-15:00	Panel Discussion
	MODERATOR Steven HU, PhD Chief Technical Officer, Everest Medicine

ICH Da	ау	ICH	
Educa	tional Worksho	p 🖲	
Openi	ng Plenary		
Global Townh	Regulatory		
	Regulatory al Session		$\mathbf{O}$
Regul	atory Science	ſ	
Drug ( Develo	Clinical opment		
Patient ( and Qua	Centered Clinical Ope lity Management	rations	
	al Needs and latform		
Data S	Science		
Biosta	tistics	(il	
PV & [	Drug Safety	()	
СМС		÷	
Transl	ational Medici	nes 📝	
Non-cl	inical & Animal Te	est	
Medic Public	al Writing and ation	Ê	
	tric Drug opment Forum	×	
		SAMUL	

## Thursday | December 8<sup>th</sup> | ICH DAY

#### Workshop 6 | 10:00–15:00

ICH Safety Guidelines: Nonclinical Safety Strategy Supporting FIH and Development of Modern Modalities

#### **PROGRAM CO-CHAIRS**

Qingli WANG, PhD Director, Office of Pharmacology and Toxicology, CDE, NMPA. China

Jack XIE, PhD Head of Preclinical Sciences and Translational Safety, Janssen R&D

NMPA, China Joined ICH in 2017. To date, all ICH safety guidelines were officially announced to be implemented. The ICH M3 guideline for non-clinical studies supporting human clinical trials and NDA is also expected to be in a process of implementation soon in China. In this session, the safety guidelines China implementation status and prospective will be discussed with views from both CDE and industry. Progress and prospect of ICH M3 China implementation and new scientific/regulatory trends of selected safety guidelines (ICH S1, S2, S5, S6, S9, and S11) will also be covered.

#### General Requirements for Nonclinical Package Supporting FIH Qingli WANG, PhD Director, Office of Pharmacology and Toxicology, CDE, NMPA, China

Animal Species Selection for Biologics Nonclinical Safety Study Xiaobo CEN, PhD CEO, WestChina Frontier Biotech

### Dose Levels Selection in Toxicology Study, Human Safety Starting Dose and Exposure Ceiling Based on Toxicology Outcomes Jack XIE, PhD

Head of Preclinical Sciences and Translational Safety, Janssen R&D

#### Safety Pharmacology Studies Considerations for FIH **CDE** Speaker Invited

Nonclinical Safety Evaluation and ICH S12 Updates on Nonclinical Biodistribution Study of Gene Therapy Product **CDE** Speaker Invited

#### Nonclinical Safety Evaluation on Cellular Therapy Product

Jing MA, PhD Chief Advisor, Shanghai Lingang Economic Development Group Co., Ltd.

#### Panel Discussion

All Speakers

Hot Topics

ICH Day	ІСН
Educational Workshop	<b>()</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	ns 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

Hot Topics

## Thursday | December 8<sup>th</sup>, 2022 | Pre-conference Short Courses

Short Course 1 | 15:30 - 18:00

PROGRAM CO-CHAIRS Xiaoyuan CHEN, MD, PhD Director, GCP Officer, Beijing Tsinghua Changgung Hospital

Rose GAO RA Head, Novartis

The History, Current Status and Prevision of China Drug Labeling Management System Guideline CDE Speaker Invited

Experience Learning of International Drug Labeling Management System Lei ZHANG JnJ

Yang LIU

Experience and Suggestions on Drafting New Drug Labeling - Industrial Perspective Kun XIA Head of Ophthalmology and Neurology Registry, Novartis

Hongying WEI Medical Director of Jiangsu Hausen Pharmaceutical Group Co., LTD

BeiGene Speaker Invited

**Panel Discussion** 

ICH Day	Thurso	day   December 8 <sup>th</sup> , 2022   Pre-conference Short Courses
Educational Workshop	Short Course 2 Regulatory	15:30- 18:00 Requirements of Medical Coding in Clinical Trials
Opening Plenary	PROGRAM CHA	
Global Regulatory Townhall	Daniel LIU, Pł Chief Scientific	D Officer, Clinical Service Center
China Regulatory Special Session	published, which of entry, index,	sting to implement the ICH M1 related to medical coding practice in China clinical trials on July 1 2022. MedDRA is one of the ICH guidelines the is adapted in the drug R&D process of regulatory managements from IND to NDA life cycle, ensuring the scientific and regulatory compliance assessment and reporting of clinical data. This session is discussing how to implement this MeDRA practice in a process of clinical trials ing relative clinical staffs compliant well with the regulatory MedDRA expectations by NMPA for pharmaceutical enterprises in China.
Regulatory Science	15:00-15:30	Outlines of MedDRA
Drug Clinical Development		Yuxiu LIU, Professor Professor and Chief Physician, Department of Critical Case Medicinent of General Hospital Eastern Zone of China
Patient Centered Clinical Operations	15:30-16:30	Coding Rule and Techinques of MedDRA
Clinical Needs and Trial Platform		Pansie ZHANG Senior Coding Specialist, Merck (China)
Data Science	16:30-17:00	MedDRA Coding Exercises
Biostatistics		Pansie ZHANG Senior Coding Specialist, Merck (China)
PV & Drug Safety	17:00-18:00	Outline of MedDRA SMQ Reporting Analysis
смс		Junchao CHEN, PhD Medical Officer, MSSO
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		2022 DIA China Annual Meeting 11

ICH Day	ІСН
Educational Workshop	
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	s 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

## Thursday | December 8<sup>th</sup>, 2022 | Pre-conference Short Courses

Short Course 3 | 15:30 - 18:00 | Real World Data Progress - Quality, Standard and Application

#### PROGRAM COMMITTEE

Ling SU, PhD Fellow of DIA Professor in Shenyang Pharmaceutical University and a Venture Partner with Lilly Asia Ventures

Shanmei LIAO, PhD Head, Post-market Statistics, BeiGene

Qiang Ll, PhD Bl Ting WU, PhD Senior Director, Lilly

Haijun CAO, PhD Asia Non-Oncology Lead, Takeda China

Shusen LIU Head of Medical Research and Innovation, Janssen Department of Medicine

#### A Case Study of Phase III Ranomized Trial with Hybrid Control Shuyi SHEN Product Development China Clinical Science Head, Roche

Real-world Evidence as Part of the Totality-of-Evidence to Inform Indications in a New Population Jeff LANGE Observational Research Director, Amgen

#### Panel Discussion: Real Data Quality and Standard

ICH Day		ICH	Thu
Educatio	onal Workshop	<b>(</b> )	Short Cour Inspect
Opening	g Plenary		PROGRAM Winnie W
Global R Townhal	Regulatory II		Director of
	egulatory Session		Hellen ZH Senior Dire
	ory Science		China has standardiz field of ph
Drug Cli Develop	inical oment		Under this capability
Patient Cer and Quality	ntered Clinical Operation V Management	s A	we have th This works
Clinical Trial Pla	Needs and tform		China PV NMPA Spe
Data Sci	ience		<b>Foreign F</b> Speaker In
Biostati	stics		Panel Dis Panelists II
PV & Dr	ug Safety		i unclists il
СМС			
Translat	tional Medicines		
Non-clini	ical & Animal Test		
Medical Publicat	Writing and ion		
Pediatri Develop	c Drug oment Forum	<b>X</b>	
Hot Top	ics		

## Thursday | December 8<sup>th</sup>, 2022 | Pre-conference Short Courses

hort Course 4 | 15:30 - 18:30 Inspection Readiness via a Comprehensive PV QMS

#### PROGRAM CO-CHAIRS Winnie WU

Director of Medical Insights and PMO, Boehringer Ingelheim

#### Hellen ZHANG Senior Director of PV, Beigene

China has entered the stage of full implementation of the "GVP". The "Guideline for Pharmacovigilance Inspection (Draft for Comment)" issued by NMPA standardizes the principles for drug regulatory authorities to carry out pharmacovigilance inspection. It indicates that inspection will become the norm in the field of pharmacovigilance.

Under this environment, it is an urgent need to understand the regulatory requirements properly, enhance the PV quality management system, establish the capability of the inspection readiness, including the timely identification of problems of the PV system, develop the effective CAPA in a timely manner, so that we have the confidence to take the inspection in stride.

his workshop will focus on PV inspection readiness and capability establishment to have deep discussion with participants

#### China PV Inspection Guideline and Practice Sharing NMPA Speaker Invited

Foreign PV Inspection Experience sharing & Learning Speaker Invited

Panel Discussion – Elements of a Smooth Inspection Panelists Invited

ICH Day	Thursday   Decemb
Educational Workshop	Short Course 5   15:30 - 18:00 Target Trial Emulation
Opening Plenary	PROGRAM CO-CHAIRS Lihong Huang, PhD
Global Regulatory Townhall	Department of Biostatistics, Zhongshan Hospital, Fu
China Regulatory Special Session	Jiawei WEI, PhD Director, Biostatistics, Novartis
Regulatory Science	The Target Trial was formally proposed by Hernan a plan is Target Trial Emulation. The aim is to bridge t
Drug Clinical Development	It is a new concept of RWS, which applies the desig research, and facilitates the transformation from RV We hope to discuss this topic in depth this year.
Patient Centered Clinical Operations	New Concept of RWS: The Value of Simulated Zhao YANG, PhD
Clinical Needs and Trial Platform	Supervisor, Department of Biostatistics, Nanjing Me Causal Inference as the Glue: Lessons from Ta
Data Science	Theis LANGE Head of Department, Professor, Department of Pub
Biostatistics	Challenges in the Emulation of Target Trials a Garcia de Albeniz Martinez XABIER Director of Epidemiology at RTI Health Solutions, V
PV & Drug Safety	Defining Causal Questions for a Single-Arm To CO-PRESENTERS
смс	Lisa Hampson Director, Biostatistics, Novartis
Translational Medicines	<b>Yi CHENG</b> Deputy Director, Biostatistics, Novartis
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

## per 8<sup>th</sup>, 2022 | Pre-conference Short Courses

Fudan University

and Robins in 2016. The process of using observational data to complete the Target test according to the set the gap between RCT and observational research and link observational research with RCT.

ign and analysis ideas of RCT to observational research, improves the level of evidence of observational RWD to RWE. Duplicate RCT was presented at the DIA 2020 Annual Meeting and case studies were presented.

## ed Target Trials

1edical University

## Target Trial Emulation in Register Epidemiology

Iblic Health, University of Copenhagen

### and Design Approximations to Address Them. Visiting Scientist at CAUSALab of Harvard T.H. Chan School of Public Health

Trial with an External Control Arm: An Application of the Target Trial Framework in Oncology.

ICH Day	Thursday   Decemb	oer 8 <sup>th</sup> , 2022   Pre-col	nference Short Courses
Educational Workshop	Short Course 6   15:30 - 18:00 When Medical Affairs Meet Clinical I	Development	
Opening Plenary	PROGRAM COMMITTEE		
Global Regulatory Townhall	Haidong CHI, MD, PhD CMO, Lilly	<b>Yi LIU</b> Chief Medical Officer and Senior Vice President, Caidya Biopharmaceutical Co., Ltd	Haijun CAO Asia Non-Oncology Lead, Takeda China
China Regulatory Special Session	How do New Therapies Stand out from the		
Regulatory Science	MA REPRESENTATIVE Jie CHEN CMO, Beiheng Biotech	CLINICAL REPRESENT. Wei WANG Clinical Development V	ATIVE /P, Head of MA, CARsgen Therapeutics
Drug Clinical Development	Panel Discussion MODERATOR Yi LIU		
Patient Centered Clinical Operations and Quality Management	Chief Medical Officer and Senior Vice President, C	aidya Biopharmaceutical Co., Ltd	
Clinical Needs and Trial Platform	Value Maximization in Phase III Clinical Stud MA REPRESENTATIVE	CLINICAL REPRESENT.	ATIVE
Data Science	<b>Zihuan GUO</b> Head, Oncology Area, Takeda Panel Discussion	<b>Jin WANG</b> Chief Medical Officer, A	Abbotz Pharmaceuticals
Biostatistics	MODERATOR Haidong CHI, MD, PhD CMO, Lilly		
PV & Drug Safety	INVITED PANELIST Mu SUN		
смс	Vice President, BD, NeuKio Clinical Study or the Real World Study? This	s is a Question	
Translational Medicines	MA REPRESENTATIVE Haijun TIAN, PhD Executive Director, RWS, Novartis	CLINICAL REPRESENT. Yue WANG, PhD Head of Digitalization a	ATIVE and Data Innovation, Vice President, Astrazeneca Global
Non-clinical & Animal Test	Panel Discussion	R&D China Center	
Medical Writing and Publication	MODERATOR Haijun CAO Asia Non-Oncology Lead, Takeda China		
Pediatric Drug Development Forum	INVITED PANELISTS		
Hot Topics	Tong GUO, PhDLiheng NVice President, BD, IQVIAPfizer	IA	2022 DIA China Annual Meeting 15

\_

ICH Day	Thurso	day   December 8 <sup>th</sup> , 2022   Pre-conference Short Courses
Educational Workshop	Short Course 7	
Opening Plenary	PIC/S Forur MODERATOR	
Global Regulatory Townhall	Xiangyu WAN NMPA	GAL O
China Regulatory Special Session	16:00 - 16:10	Welcome Address
		NMPA Speaker Invited
Regulatory Science	16:10 - 16:40	Revised Quality Risk Management Requirements of ICH Q9
Drug Clinical Development		Kevin ODONNELL Member of PIC/S Member of HPRA
Patient Centered Clinical Operations	16:40-17:10	Related Requirements of Asepsis Appendix
Clinical Needs and Trial Platform		lan Thrussell
Data Science	17:10-17:30	Introduction of Clinical Trial Appendix
Biostatistics		CFDI Speaker Invited
PV & Drug Safety		
смс		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		

Jun Market

Hot Topics

ional Workshop	9:00-9:05	Welcome		
у 🖉		WANG Tongyan, PhD Managing Director, DIA China	1 and the second second	
	9:05-9:15	Program Co-chaimen Welcome Address		
		<b>Lili CAO</b> Co-chair of 2022 DIA China Annual Meeting Deputy Director, China International Food and Drug Exchange Center (CCFDIE), NMPA		
		<b>Wendy YAN</b> Co-chair of 2022 DIA China Annual Meeting VP and Head of RA, BeiGene		
	9:15-9:30	Welcome Speech of Leader of The National Medical Product Administration		
	9:30-9:35	Welcome Speech of Leader of Ministry of Science and Technology		
	9:35-9:40	Welcome Speech of Suzhou Local Government		
	9:40-10:05	Keynote Speech 1   Innovative Achievements of NMPA		
		NMPA Commissioner Invited		
<i>(</i> )	10:05-10:30	Keynote Speech 2 Innovation and Collaboration: The Role of Clinical Trials and International Collabora	ation	
		Emer Cooke Executive Director, EMA		
es 👔				
Test				
'				
ım				
				J

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	s 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	ר
Hot Topics	

## Friday | December 9<sup>th</sup> | OPENING PLENARY

10:30-11:20	Opening Special Forum: Collaboration, Innovation – China Innovative Drug Globalization Pathway					
	MODERATOR					
	Shun LU, MD					
	Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital, Shanghai Jiaotong University					
	CDE Panelist Invited					
	WANG Vensium Drefessor					
	WANG Yongjun, Professor President, Beijing Tiantan Hospital					
	Zili LI, MD					
	Vice President, Head of Asia Pacific R&D, Janssen Research & Development					
	Weikang TAO, PhD					
	Vice President and General Manager, Qilu Global Innovative Drug Research and Development					
	Jin Wang					
	Partner, McKinsey & Company					
11:20-11:50	2022 DIA China Inspire Award Ceremony					

ICH Day	ІСН	E
Educational Workshop	<b>()</b>	G
Opening Plenary		Glok and
Global Regulatory Townhall		13:30
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operatio and Quality Management	ns 🔏	
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety	$\overline{\mathbf{Y}}$	
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum	ר	
Hot Topics		

## Friday | December 9<sup>th</sup> Global Regulatory Modernization Townhall

Global Regulatory Modernization Townhall on May 20 will invite the regulators from China NMPA, US FDA, EMA and PMDA to share their regulatory responses and key innovative initiatives to against COVID-19 Pandemic in order to save people and protect public health, also their lessons learned.

30-15:00	Regulatory Responses and Key Innovative Initiatives to Against COVID-19 Pandemic			
	MODERATOR			
	NMPA Moderator Invited			
	13:40-14:00 NMPA Update			
	Department of Registration, NMPA			
	14:00-14:20 FDA Update			
	Kevin B Bugin, MS, PhD, RAC			
	Deputy Director of Operations			
	Office of New Drugs, CDER, FDA			
	14:20-14:40 PMDA Update			
	Nobumasa Nakashima, PhD			
	Associated Executive Director for International Programs			
	Pharmaceuticals and Medical Devices Agency (PMDA)			
	14:40-15:00 EMA Update			
	Alexis NOLTE			
	Head, Human Medicine Division, EMA			

ICH Day	Friday	December 9 <sup>th</sup>		
Educational Workshop		Regulatory Modernization Townhall		
Opening Plenary	15:00–17:00	NMPA Townhall		
Global Regulatory Townhall		Promote Global Regulatory Collaboration NMPA Department of Science, Technology, and International Cooperation Speaker Invited		
China Regulatory Special Session		Key Initiatives to Accelerate Drug Review and Approval Process NMPA CDE Speaker Invited		
Regulatory Science		5 Years Review of China Drug Inspection NMPA CFDI Speaker Invited		
Drug Clinical Development		Drug Safety NMPA CDR Speaker Invited		
Patient Centered Clinical Operations	17:00-17:05	Thanks Address by DIA Global CEO		
Clinical Needs and Trial Platform		Barbara Lopez KUNZ Global CEO, DIA		
Data Science	17:05-17:10	Closing		
Biostatistics				
PV & Drug Safety				
смс				
Translational Medicines				
Non-clinical & Animal Test				
Medical Writing and Publication				
Pediatric Drug Development Forum				
Hot Topics			2022 DIA China Annual Meeting	20

ICH Day	ІСН	
Educational Workshop	Ō	-
Opening Plenary		1
Global Regulatory Townhall		
China Regulatory Special Session		1
Regulatory Science		-
Drug Clinical Development		(
Patient Centered Clinical Operation: and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		-
Hot Topics		

#### THEME LEAD

Wendy Yan Senior Vice President, Head of Regulatory Affairs BeiGene (Beijing) Co., Ltd.

Jianqing CHANG Vice President, Drug Regulatory Policy, Tigermed

Irene DENG Vice President, Regulatory Affairs Head, Sanofi Angela YAN President, R&D and Operations, China & Asia, Kira Pharma

Xiaoyuan CHEN, PhD Director, GCP Officer, Beijing Tsinghua Ch<mark>anggung Hospital</mark>

Joyce LIU China Regulatory Affairs Head, Takeda

#### Session 0101 | December 10, 2022

08:30-10:00

#### Expedited Program under New Regulations - Considerations & Practices

#### SESSION CO-CHAIRS

Lihua PAN Head of China Regulatory Policy, Global RA, GDD, Novartis Lei ZHANG RA Head, Janssen

Speeding up the review policy is one of the important international measures to encourage drug innovation and benefit patients as soon as possible. With the introduction of new drug administration laws, registration regulations and guidelines to speed up review and approval, for example

Breakthrough therapeutics, conditional approval, AD hoc approval procedures, and existing guidelines such as priority review and approval have been updated. This topic is intended to invite representatives of drug regulatory bodies and industry from the regulatory

To explore the mechanisms of accelerated review and approval at home and abroad from the institutional and industry perspectives, share successful cases and suggestions, and guide the industry to accelerate drug development process.

CDE Expedited Review Policy Analysis and Suggestions

CDE Speaker Invited

China and the United States to Speed up the Case Sharing and Thinking Yanyan WEI RA Group Lead, Novartis

China Synchronous R&D and Submission Sharing and Thinking Jian CHEN Head of Immune Inflammation Regulation, Boehringer Ingelheim

Review and Approve Case Study Hui YAN Senior Director, Pharmaceutical Affairs, BeiGene

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

#### Session 0102 | December 10, 2022

10:30–12:00 Challenges and Considerations from Accelerated Approval to Full Approval

#### SESSION CHAIR Wendy YAN SVP, Chief Regulatory Officer, Beigene

After formal implementation of accelerated approval in China, dozens of products have been approved under this pathway. In the coming years both health authorities and sponsors will be faced with how to achieve full approval through confirmatory clinical trials and how to deal with the various possibilities of the results from confirmatory trials.

This session will invite experts from NMPA and FDA, as well as industry experts in China to discuss the challenges of accelerated approval and confirmatory study design.

Challenges and Recommendations for Confirmatory Clinical Studies after Accelerated Approval **Vivian ZHANG** Director, Regulatory Affairs, BeiGene

The Current Considerations of the Confirmatory Study Design and the Management of the Trial Results CDE Speaker Invited

#### FDA's Thinking and Experience on Accelerated Approval and Confirmatory Study Design Wenny DU, MSc

Director, Global Regulatory Lead (GRL) for Oncology, Amgen Inc., United States

#### Panel Discussion

Panelists: Above Speakers and Invited Panelists Xiaoyuan CHEN, PhD Executive Director of Clinical Trial Center, Tsinghua University

Lihua PAN Head of China Regulatory Policy, Global RA, GDD, Novartis

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0103-A | December 10, 2022

13:30–15:00 The Opportunity and Challenge Under the Concept of Clinical Value-Oriented Drug Innovation- Part 1

#### SESSION CHAIR

Jianqing CHANG

Government Regulation Affairs, Hangzhou Tigermed Consulting Co.,Ltd.

The concept of "Encouraging clinical value-oriented drug innovation" has been proposed for the first time ever since the launch of drug review and approval reform in 2015. Then this concept is re-emphasized in the new <Drug Administration Law>, the new <Drug Registration Regulation>. In the < Guideline for Clinical Development of Clinical Value-Oriented Oncology Drugs(seeking for public's opinion's version)>issued on July 2, 2021, it is focusing on clinical value-oriented and patient needs-oriented R&D. This guideline is not only a summary of the exploration, practice and accumulation of the concept that has been implemented for nearly six years for the review and approval of oncology drugs, but also applicable to all therapeutic areas, including oncology and non-oncology therapeutic areas, rare diseases and pediatric diseases, etc. Through the sharing and discussion between health authority and industry, especially with the selected cases, we hope to bring inspiration and help to the development of new drug development and registration strategies.

Progress of Review and Approval based on Clinical Value CDE Speaker Invited

Differentiated Development Strategy based on Clinical Value -- Clinical Perspective Bin PENG, PhD Chief Medical Officer, Anmai Biology

Clinical Value-oriented Differentiated Development Strategy -- Registration Perspective Irene DENG Vice President, Regulatory Affairs Head, Sanofi

#### Panel Discussion

Above Speakers and Invited Panelists Xia CHEN, MD, PhD Senior Vice President, Chief Medical Officer, Tiger Pharmaceuticals

ICH Day	ICH
Educational Workshop	<b>(</b> )
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0104-A | December 10, 2022

16:00–17:30 The Opportunity and Challenge Under the Concept of Clinical Value-Oriented Drug Innovation- Part 2

SESSION CHAIR Angela YAN President, R&D and Operations, China & Asia, Kira Pharma

The concept of "Encouraging clinical value-oriented drug innovation" has been proposed for the first time ever since the launch of drug review and approval reform in 2015. Then this concept is re-emphasized in the new <Drug Administration Law>, the new <Drug Registration Regulation>. In the < Guideline for Clinical Development of Clinical Value-Oriented Oncology Drugs(seeking for public's opinion's version)>issued on July 2, 2021, it is focusing on clinical value-oriented and patient needs-oriented R&D. This guideline is not only a summary of the exploration, practice and accumulation of the concept that has been implemented for nearly six years for the review and approval of oncology drugs, but also applicable to all therapeutic areas, including oncology and non-oncology therapeutic areas, rare diseases and pediatric diseases, etc. Through the sharing and discussion between health authority and industry, especially with the selected cases, we hope to bring inspiration and help to the development of new drug development and registration strategies.

Clinical Value based Regulatory Strategy Case Sharing Wen GU RA Head of Specialty Care (non-rare) and Primary Care BU, Sanofi

Clinical Value based Drug Development Case Sharing - Oncology Long CHENG, PhD Vice President, RemeGen

Clinical Values based ICH E9(R1) Naiqing ZHAO Chief Scientific Officer, Caidya Biopharmaceutical Co., Ltd

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

Session 0105-A | December 11, 2022

08:30-10:00 How to Further Promote the Convergence and Consistency of Global Supervision - Regulatory Innovation Trend in China, Japan, Europe and the United States

#### SESSION CO-CHAIRS

Fei ZHENG Head Immunization, RA, Abbvie

Julia LUAN, PhD Senior Director in Global Regulatory Affairs, Astrazenca

In China, Japan and the United States analyze the new regulatory trends of different national regulatory authorities by introducing the new regulations, policies, new measures and regulatory concepts introduced by China (NMPA), Japan (PMDA), the United States (FDA) and Europe (EMA) regulatory authorities in recent years.

On September 17, 2019, FDA announced a framework plan called the ORBIS project. The Orbis program is an initiative program initiated by the US FDA's Center of Excellence (OCE) in Oncology, providing a collaborative framework for the synchronous submission and review of oncology products among international drug regulatory collaborating agencies. The program is coordinated by the FDA and is similar to the Access Alliance, with members including the TGA, Health Canada, the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Sciences Agency of Singapore (has), Swissmedic, and the Brazilian National Health Surveillance Agency (ANVISA).

Further Promote Convergence and Consistency of Global Regulation – Regulatory Innovation Trends in Japan, Europe and the United States CDE Speaker Invited

### New Measures and Trends in Drug Supervision in Europe and the United States **Julia LUAN, PhD** Senior Director in Global Regulatory Affairs, Astrazenca

#### Introduction of Simultaneous Approval by Multiple Regulatory Authorities (ORBIS Project) Yinghua WANG, PhD

FDA ORBIS Team member, Senior Regulatory Health Project Manager in the Oncology Center of Excellence, US FDA

ORBIS Case Sharing——Venetoclax AML Introduction Tiesch John

Director, RA Global Regulatory Strategy, Abbvie US

#### Pane Discussion: My Opinion on "Regulatory Innovation in China" PANELISTS

Speakers above and Invited Panelists Wendy Yan SVP, Chief Regulatory Officer, Beigene

Jing HE, PhD SVP, Head of China R&D Global Oncology R&D, Astrazeneca

ICH Day	ICH
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operatic and Quality Management	ons 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\overline{\mathbf{O}}$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	ר
Hot Topics	

#### Session 0106-A | December 11, 2022

10:30-12:00

Opportunities, Challenges and Suggestions for MAH Implementation in China

#### SESSION CHAIR Jie LI

Senior Vice President, RA Head, Overland Pharma

In 2015, Chinese regulation proposed for the first time to carry out the polit of drug marketing authorization holder(MAH). In 2016, MAH polit were launched in 10 provinces/municipalities.

MAH clarifies the subject of responsibility, promotes resource optimization, greatly encourages innovation, and brings opportunities to Chinese industries. However, there are still a lot of challenges.

In this session, we invited experts from PMDA and NMPA, to learn the mature experience, to hear the considerations from health authorities. We also invited the representative from Chinese industry to hear the challenges they are facing. Let's discuss together how to better implement MAH.

#### Regulatory Experience of MAH Implementation in Japan

Yuji MATSUKURA Deputy Director, Office of International Regulatory Affairs, Ministry of Health, Labour and Welfare (MHLW)

Opportunities and Challenges Faced by Chinese Heath Authorities in the Process of MAH Implementation NMPA Speaker Invited

#### Opportunities and Challenges Faced by Chinese Industries in the Process of MAH Implementation May Li

VP, Head of Regulatory Affairs, China/Japan, Beigene

#### Panel Discussion

PANELISTS Speakers above and Invited Panelist Huina WANG Regulatory Director, China R&D Center, Johnson & Johnson

Jianqing CHANG Vice President, Drug Regulatory Policy, Tigermed

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

## Regulatory Science - Global Regulatory New Trend

Session 0105-B | December 11, 2022

8:30-10:00 FDA Session: Communicating with the FDA: Best Practices to Overcome Drug Approval Barriers and Regulatory Challenges

SESSION CHAIR Latasha ROBINSON Acting Country Director, FDA China Office

Generic drugs provide significant public health benefits by providing high-quality, more affordable alternatives to brand name drugs. Approximately 90 percent of prescriptions dispensed in the United States are generic drugs that often are the product of an intricate global supply chain. The Office of Generic Drugs (OGD) is involved in efforts intended to advance the international harmonization of scientific, technical and regulatory standards for generic drug development. OGD continues global efforts with a focus on prioritizing future topics for generic harmonization that will include more complex generic drugs. The envisioned outcome of these global efforts is reduced time and cost of product development consequently improving patient access to more affordable medicines. OGD global affairs identifies opportunities and challenges as those national regulations are being developed and implemented positioning regulators proactively on the path of convergence.

## Communicating with the FDA: Inspections & Remote Regulatory Assessments Jonathan CHAPMAN

Medical Product Supervisor, FDA China Office

#### OGD Global Affairs Program and Global Engagement Sarah IBRAHIM, PhD, PharmD

Associate Director for Global Generic Drug Affairs, Office of Generic Drugs (OGD); Office of Center for Drug Evaluation & Research (CDER), FDA

Q&A

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

## Regulatory Science - Global Regulatory New Trend

#### Session 0106-B | December 11, 2022

10:30-12:00 PMDA & JPMA Joint Session, How Japanese Regulatory Authority and Industry Responded to Manage Clinical Trials under COVID-19 Pandemic

#### SESSION CO-CHAIRS

Nobumasa Nakashima, PhD Associate Executive Director for International Programs and Asia Training Centre Pharmaceuticals and Medical Devices Agency (PMDA), Japan

#### Sachiko NAKAGAWA, MPH

Managing Director, Japan Pharmaceutical Manufacturers Association (JPMA), Japan

#### Regulatory Responses to COVID-19 in Japan

Yuji MATSUKURA Deputy Director, Office of International Regulatory Affairs, Ministry of Health, Labour and Welfare (MHLW)

## Regulatory Agility for Clinical Development under the COVID-19 Pandemic Daisuke KOGA

Division Director, Division of Planning and Management, Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA)

## Industry's Efforts on Clinical Trials Conduct under Pandemic Toshiharu SANO

Vice-Chairperson, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA)

ICH Day	ІСН	
Educational Workshop	$\overline{\bigcirc}$	
Opening Plenary		
Global Regulatory Townhall	$\bigcirc$	
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operations and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum		

Hot Topics

# **Drug Clinical Development**

### THEME LEAD

Shun LU, MD, PhD Director, Center for Clinical Medicine of Lung Cancer Shanghai Chest Hospital, Shanghai Jiaotong University

### Jing HE, MD, PhD

SVP, Head of China R&D Global Oncology R&D, Astrazeneca

Xingli WANG, MD, PhD ACC Member, DIA

### Zhaohua CHEN

Head of Global Climical Data Services, Pfizer China R&D Center

#### Jessie ZOU, MD, PhD President, Global R&D, Junshi Biosciences

Pei HU, MD, PhD Co-founder, Beijing Lingchu Tech

Gailing LI, PhD Chief Scientist Officer, Certara

	Session 0201 A	December 10, 2022		
red Clinical Operations	Session 0201-A	December 10, 2022	<u> </u>	
	08:30-10:00	Drug Development in Cardiovascular Diseases	a – Challenges and Opportunities	
eeds and units orm	)	SESSION CO-CHAIRS		
		Haiyan Ll		
ence	)	Director of Drug Clinical Trial Institution, Chief Physi	cian of Cardiovascular Medicine, Peking University Thi	rd Hospital
		Xingli Wang, MD, PhD		
ics	)	ACC Member, DIA		
		New Progress in Drug Development of Heart Failure		
		Jian ZHANG, MD		
g Safety	·		e Center, Fuwai Hospital, Chinese Academy of Medical	Sciences
		Director, Key Laboratory of Cardiovascular Drugs Cl	inical Research, National Health Commission	
( <del>·</del>		A Regulatory Approach to Accelerate Cardiovascula	r Drug Development	
		CDE Speaker Invited		
onal Medicines 🛛 📝	)	Translational Research: Case Studies on the Transfo	mation of Laboratory Findings into Clinical Studies	
		Guoping YANG		
al & Animal Test	)	Professor, Director of Translational Medicine Center	of Xiangya Third Hospital	
		First in class Drug Development for Cardiovascular I	Disease	
Vriting and		Baoxue YANG, MD, PhD		
on 📃		Deputy Dean, Director, Department of Pharmacolog	y, School of Basic Medical Sciences, Peking University	

ІСН Дау	Drug Cl	inical Development		
Educational Workshop	Session 0202-A	December 10, 2022		
Opening Plenary	10:30-12:00	Neurology & Psychiatry Drug Development		
Global Regulatory Townhall		SESSION CHAIR Yifeng SHEN Director of drug Clinical Trial Institution Office of Shanghai Mental Health Center		
China Regulatory Special Session		Global and Chinese Antidepressant Market and Clinical Development Progress Report Yifeng SHEN Director of drug Clinical Trial Institution Office of Shanghai Mental Health Center		
Regulatory Science		Current Status of Global Alzheimer's Drug Development		
Drug Clinical Development		Yaning WANG, PhD CEO of Lanlai Technology Former Director, Quantitative Pharmacology division, U.S. FDA		
Patient Centered Clinical Operations	Session 0203-A	December 10, 2022		
Clinical Needs and	13:30-15:00	Breakthrough of Rheumatism Immunotherapy		
Trial Platform		SESSION CHAIR Yingyue JU Head of Clinical Development, Pfizer China		
Biostatistics		Focus on the hot spots and pain points of clinical research and development of immune dermato immune skin diseases, and share the experience of remote clinical research of dermatology.	logy, explore the precise treatment of	
PV & Drug Safety		A New Era in Immunological Picot Research <b>Xinghua GAO</b> Director of Dermatology, Deputy Director, The First Clinical College of China Medical University		
смс		Exploration of Precise Treatment of Immune Skin Diseases Yang CUI		
Translational Medicines		Head of Immune Inflammation Research and Development, Pfizer China		
Non-clinical & Animal Test		Reflection on Differences in Diagnostic/Evaluation Criteria between Clinical Research and Clinical <b>Ting Ll</b> Deputy Chief Physician, Renji Hospital, Shanghai Jiaotong University School of Medicine	Practice	
Medical Writing and Publication				
Pediatric Drug Development Forum				
Hot Topics			2022 DIA China Annual Meeting	30

by IC	Drug C	linical Development	
ional Workshop		• A   December 10, 2022	
ng Plenary	16:00-17:30	Vaccine Development	and i
Regulatory all	9	SESSION CO-CHAIRS Pingping LI Director of Life Science Investment, SDIC Investment	Shengmei MU Senior Director, Senior Category Development Lead
Regulatory al Session	<b>Î</b>	Management Co., LTD	- Rare Disease & Vaccine, Pfizer
		This session mainly focused on the evolution of COVID-19 significance of new technology vaccines compared with va	vaccine research and development in the era of COVID-19, and the reference accines of other diseases.
nical	5	Interpretation of Principles for the Development of Multiva CDE Speaker Invited	lent Vaccines Guideline
ment tered Clinical Operations		Progress in Sequential Strengthening of COVID-19 Vaccine Hongxing PAN Director of Vaccine Clinical Evaluation Institute, Jiangsu Ce	
Needs and Iform		COVID-19 Vaccine Technical Standards and Detection Pers Speaker Invited	pectives
ence		Application of mRNA Vaccine in COVID-19 and Other Disea Hangwen LI, PhD CEO, StemiRNA	ases
tics		Building an Immune Barrier for Newborns - Global Advanc	es in Maternal Immunity
g Safety		<b>Qiaohong LIAO</b> Director of Vaccine Clinical Research and Development, Pfi	izer (China) Research and Development Co. LTD
	Session 0205-/	A   December 11, 2022	
	8:30-10:00	Infection Disease Drug Development	
onal Medicines		SESSION CHAIR Sunny ZHU	
al & Animal Test		Chief Medical Officer, Everest Medicines New Guidance Updates of EMA/FDA for Drug Developmer	nt of Anti-bacterial Products
Writing and ion		<b>Rienk Pijpstra</b> VP, Portfolio Head of Anti-bacterial Product, Pfizer	
: Drug ment Forum		Innovative Research and Development of China's first COV <b>Yao ZHANG</b> Vice President, Clinical Research, Brii Biosciences	ID-19 Neutralizing Antibody Drug
cs			2022 DIA China Annual Meeting

ICH Day	ІСН	
Educational Workshop	<b>()</b>	
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operations and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum		
Hot Topics		

Session 0206-A | December 11, 2022

10:30-12:00

Metabolic Endocrinology SESSION CHAIR Yi LIU Chief Medical Officer and Senior Vice President, Caidya Biopharmaceutical Co., Ltd Diabetes Drug Development: Going beyond Hypoglycemic-centric Linong JI Director, Department of Endocrinology, Peking University People's Hospital Director, Peking University Diabetes Center Medical Strategy Layout of Innovative Products in New Field Jun YANG, PhD Chief Medical Officer, VISEN

Design of Clinical Trial Protocol for Innovative Drugs in the Area of Diabetes and its Complications based on ICH E9R1 Naiqing ZHAO Chief Scientist Officer, Caidya Biopharmaceutical Co., Ltd

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

### Oncology Drug Clinical Development

#### Session 0201-B | December 10, 2022

8:30-10:00

Collaboration and Acceleration for Cancer Cure - Hot Topics in Oncology Development

#### SESSION CO-CHAIRS

Xiaoyuan CHEN, MD, PhD Director, GCP Officer, Beijing Tsinghua Changgung Hospital

#### Ke LIU, PhD Head of Regulatory Affairs & Strategy, Sana Biotechnology

The main objective of the session is to discuss the ways for collaboration among different stakeholders to accelerate the oncology drug development. The audience will be industry attendees from China domestic companies and multi-national companies; academicians from university, university hospitals and cancer research centers; and regulators (mainly from China NMPA).

### Project Catalyst Which is an OCE Initiative to Foster the Oncology Development Jeffery SUMMER, PhD

Associate Director for Translational Sciences, Office of Oncologic Diseases, CDER, FDA

#### Changes in Guidelines for Combination Therapy and Clinical Trial China CDE Speaker Invited

Pediatric Oncology Drug Development and Unmet Needs from the Patient Group Perspective **Zhizhong LI, PhD** Director, Pediatric Oncology Foundation

#### Panel Discussion

ICH Day	ICH
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

Session 0202-B | December 10, 2022

10:30–12:00 Statistical Innovations and Practical Considerations for Oncology Drug Development

### SESSION CHAIR Meng CHEN, PhD

AZ

Progress in better understanding of cancer biology together with the competitiveness of oncology drug development has caused a shift in oncology trial designs. This session will showcase a few presentations covering the advancement in early phase oncology trial design, statistical considerations for basket trials with Bayesian hierarchical model as one example, practical considerations for master protocols, and what to consider to transform external data to external evidence.

Advanced Statistical Designs for Dose Optimization in Oncology Clinical Trials Yuan JI, PhD Professor of Biostatistics at University of Chicago

Statistical Considerations in Basket Trials and Master Protocol Julie CONG, PhD Head of Biometrics Everest Medicines

Practical Considerations for Master Protocols Rui MIAO, PhD Associate Director, AstraZeneca R&D China Statistics

From External Data to External Evidence – What to Consider and How to Proceed **Fan XIA, PhD** Head of Data Science Center, CSPC Pharmaceutical

ICH Day	ІСН	
Educational Workshop	<b>()</b>	
Opening Plenary		
Global Regulatory Townhall	$\bigcirc$	
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operations and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

Session 0203-B | December 10, 2022

13:30-15:00 Anti-PD1/L1 Bispecific Antibody

#### SESSION CHAIR

Wenjuan ZHENG Head of China Clinical Development-Solid Tumor, VP, BeiGene

Currently, immunotherapies are widely used for the clinical treatment of various tumor types. Although immunotherapies have shown significant and long-term efficacy in cancer patients, their clinical benefits in the overall population are still low because of limitations and challenges such as low response rate and resistance development. Advances in protein engineering technology have enabled the generation of various bispecific antibodies (BsAbs) that target multiple antigens as a single molecule. BsAb based immune therapeutics may have the potential to improve clinical efficacy and safety. Therefore, the interest in the development of BsAbs has grown considerably, and there are various types of BsAbs in clinical and preclinical stages. Here, we present 3 examples of BsAbs in clinical development.

AK-104: anti-PD1/CTLA-4 -- Akesobio Baiyong LI, PhD CSO, Kangfang

Anti-PD-L1/4-1BB Development Consideration Xuke QIN, PhD Chief Medical Officer, Elpiscience

	Clinical Development
ional Workshop 💿 Session 0204-	B   December 10, 2022
enary 16:00-17:30	Development of Small Molecule Drugs & New Targets of ADC Drugs
gulatory	SESSION CHAIR Haiyi GUO VP, Clinical Development- Heme, Beigene
atory ion	BTK PROTAC: In the era of biologic immunotherapy, a variety of innovative biotechnological therapies have emerged continuously, and the research and development of small molecule drugs is facing many new challenges. However, as the most traditional form of medicine
ince	although the current development of small molecule drugs has encountered some difficulties, it also has its advantages that are difficult to replace. With the development of new innovative technology platforms such as PROTAC, the strategies for small molecule clinical development will become more diverse. PROTAC largely combines the advantages of small molecule compounds and small molecule nuc acids, which can solve the resistance to traditional small molecule drugs and make it possible to target a variety of "non-drug" targets for
	research and development. Several targeted protein degradation therapies are currently in clinical development, including PROTAC, which targets BTK.
ical Operations	Drug the Undruggable: PROTAC Discovery and Development Huaging LIU
	Executive Director, Medicinal Chemistry, Beigene
	Al Promotes Undruggable Target Alex ZHAVORONKOV, PhD CEO, Insilico Medicine
	Progress and Opportunity of ADC Development <b>Vicky ZHANG</b> Senior oncology R&D Leader, Clinical Development, Pfizer China R&D Center
Session 0205-	
8:30-10:00	Application of New Technology in Oncology Drug R&D
icines	SESSION CHAIR Jessie ZOU, MD, PhD President, Global R&D, Junshi Biosciences
nimal Test	Application of Medical Imaging Technology Fused with Artificial Intelligence in Clinical Trial Xiaomei QI
and	Deputy General Manager of Imaging Science, Zhejiang Taimei Medical Technology Co., LTD Data Science to Accelerate Drug Discovery
	Weifeng WANG Vice President, R&D, OrigiMed
orum	

ICH Day	ІСН	
Educational Workshop		
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operations and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

### Novel Targets/New Modalities Drug Clinical Development

#### Session 0201-C | December 10, 2022

8:30-10:00

#### Gene Therapy in Rare Diseases

#### SESSION CO-CHAIRS

Hui XIONG, Professor Director of Pediatric Neurology Department, Peking University First Hospital

Jing YANG, PhD Head of Global Pharmaceutical Research and Development Neurological and Respiratory Area, Novartis China

#### Clinical Drug Discovery in SMA Gene Therapy - Experiences and Challenges Daniel GRANT Vice President, Novartis GDD

Basic Research and Clinical Transformation of Gene Editing in Rare Diseases Wanjin CHEN Professor, Director of department of Neurology, The First Affiliated Hospital of Fujian Medical University

The Important Role of AAV Vector Design and Quality Control in Gene Therapy **Guang QU, PhD** Co-founder, Suzhou Nuojiebei Biotechnology Co., LTD

#### Design Considerations for Clinical Studies of Rare Diseases Hongjie ZHU, PhD Director, Global Statistics & Data Science, BeiGene

#### PANEL DISCUSSION

Above Speakers and Invited Panelists Jie LI Chief Physician, Department of Digestive Oncology, Peking University Cancer Hospital Chairman of Ethics Committee of Peking University Cancer Hospital

ICH Day	ІСН	
Educational Workshop	<b>()</b>	
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operation: and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety	$\bullet$	
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum		
Hot Topics		

Session 0202-C | December 10, 2022

10:30-12:00

### CAR-T Therapies – Past, Current and Future

### SESSION CO-CHAIRS

Lei LIU Head of Global RESEARCH and Development of Hematology Therapy, Novartis China

### Zhitao YING, PhD

Professor, Lymphoma Department, Beijing Cancer Hospital

With the marketing of the two CART products in China, the cancer treatment in China officially opened the prelude to the CART era. How do regulatory authorities, physicians, and pharmaceutical companies cooperate to ensure that CART products are reasonably regulated risk control before approval, how to ensure reasonable clinical risk management during clinical studies and clinical application after product approval, how to manage and control during production, and the application prospects of immune cell products in multiple tumors, and we will conduct in-depth discussions on these topics.

### Risk Control after Cell Therapy Clinical Studies and CAR-T Product Approval Lei LIU

Head of Global Research and Development of Hematology Therapy, Novartis China

Clinical Observation of the Whole Process of CAR-T Therapy **Zhitao YING, PhD** Professor, Lymphoma Department, Beijing Cancer Hospital

### Risk Management Prior to CAR-T Product Approval - Regulatory Perspective CDE Speaker Invited

Development and Practice of Immune Cell Products in Solid Tumors Yu WANG, PhD Founder, Executive Director and CHIEF Executive Officer, co-Chief Technology Officer, Yongtai Bio

### Quality Control Strategy for CAR-T Products

Ruina SHI, PhD Vice President of Quality of Beijing Fine Arts Shenzhou Pharmaceutical Technology Co., LTD

### Panel Discussion

INVITED PANELISTS Liqun WANG, PhD Founder, Chairman and Chief Executive Officer, NeuKio

Shihu WEI Medical Director of Kuntuo Xincheng Pharmaceutical Research and Development (Beijing) Co., LTD

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	*
Hot Topics	

Session 0203-C | December 10, 2022

13:30-15:00	RNAi Therapeutics: A New Class of Transformational Medicines	
	SESSION CO-CHAIRS Chenyu ZHANG Dean, Life Science College, Nanjing University	-
	Jianyong LI Head, Metabolic Area, Vascular Nephrology, Novartis	
	An Overview of RNA-targeting Therapeutics Yang LU, PhD CEO, Sheng Nuo Bio	
	siRNA for Hypercholesterolemia: The Inclisiran Story Anastasia LESOGOR Heads up Clinical Development for Inclisiran, Novartis	
	Model-informed siRNA Clinical Research and Development <b>Rui CHEN, MD, PhD</b> Head of Phase I Study, Peking Union Hospital	
	Panel Discussion	

ICH Day	ІСН
Educational Workshop	$\overline{}$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	•
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0204-C | December 10, 2022

### 16:00–17:30 Development of Radioligand Therapies in Oncology

SESSION CO-CHAIRS Gloria GONG, PhD Former China Development Unit Head, Novartis

Woody TANG Therapeutic Area Lead, Novartis

First time in DIA China to introduce Radioligand treatment development status from regulatory, dosimetry, theragnostic, and CMC, and training of nuclear medicine specialists. It also highlights the importance of multi-disciplinary team including nuclear medicine in hospital to treat cancer patients.

### RLT Development in China and in major ICH countries – Focus Areas in Technical Guidelines and its Progress Shuang LIU

Senior Vice President of Beijing Xiantong International Pharmaceutical Technology Co., LTD

#### Dosimetry and CMC Consideration in RLT Development

Hongyu Li Senior Researcher, CIRC

### China Development Plan for Nuclear Medicine Challenges and Opportunities Including Theranostics Outlook

Gang HUANG Professor, Director of Shanghai Key Laboratory of Molecular Imaging and academic leader of Nuclear Medicine of Shanghai Renji Hospital

#### Panel Discussion: MTD in RLT Development and Treatment

FACILITATOR Woody TANG Therapeutic Area Lead, Novartis

### INVITED PANELISTS

**Rong ZHENG** Professor, Cancer Hospital, Chinese Academy of Medical Sciences

**Dr. Zhigang JI** Professor, PUMC Hospital Urology

Zheng WANG Chief Scientific Officer, DONGCHENG AMS

ICH Day	ICH	
Educational Workshop	Ō	
Opening Plenary		
Global Regulatory Townhall	$\bigcirc$	
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operatio and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication	Ê	
Pediatric Drug Development Forum		
Hot Topics		

Session 0205-C & 0206-C | December 11, 2022

Medical Sciences

#### 8:30-12:00 Al and Digital Tools in Drug Development - Part 1 & Part 2 **SESSION CO-CHAIRS** Min JIANG Wei ZHOU Director of GCP center, Beijing Cancer Hospital China Compound Team Leader, Vaccine & Immunology, J&J Al to Predict the Next COVID Outbreak for the Vaccine Enrollment Jennings XU Data Science Portfolio Management, Janssen Global **Decentralized Clinical Trial** Isaac R. RODRIGUEZ-CHAVEZ SVP, Head of Scientific & Clinical Affairs, Strategy for DCTs, ICON Decentralized Clinical Trial Case Sharing T Scott ASKIN Director, Global RA Program, Novartis Perspectives on DCT from the Site Hong FANG GCP Center operation director, Cancer Hospital Chinese Academy of Medical Sciences (CAMS) Al in Clinical Medicine **Tianyin WONG** Deputy Group CEO for Research and Education at SingHealth, Elected US National Academy of Medicine FDA Approved Medidata Synthetic Control Arm for rGBM Phase III Cases Ming ZHU Consultant, Medidata AI in Predicting Drug Targets Yu ZHAO Deputy Director of Turing Darwin Lab, Institute of Computing Technology, Chinese Academy of Sciences Co-founder of Zheyuan Technology, Ltd. Co Panel Discussion: Opportunities and Challenges in Digital Enabling Development FACILITATOR Jiming XU CEO of Happy Life Tech **INVITED PANELISTS** Dawei WU Yiwei FENG Wei LIU David XIE Cancer Hospital, Senior Director. Drug AI Technology Head, Partner at Deloitte Consulting Chinese Academy of Clinical Operations, IQVIA Tencent

ICH Day	ІСН	
Educational Workshop	<b>()</b>	
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operation and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum	*	
Hot Topics		

# **Drug Clinical Development**

Session 0205-I	D   December 11, 2022
8:30-10:00	China Clinical Pharmacology's Today and Tomorrow
1	SESSION CHAIR Gailing LI, PhD Chief Science Officer, Certara
	Considerations and Expectations behind the Chinese Clinical Pharmacology Regulations and Guidelines CDE Speakers Invited
	The Role and Responsibility of Clinical Pharmacology in Lifecycle Drug Development Ao PENG, PhD Head, Clinical Pharmacology and Early Clinical Development, Pfizer
	Confusion and Needs of Clinical Pharmacology in Drug Development of China <b>Rui CHEN, MD, PhD</b> Head of Phase I Study, Peking Union Hospital

ICH Day	ICH
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operatio and Quality Management	ns 📕
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0206-D, | December 11, 2022

10:30-12:00

Make Clinical Pharmacology a "Symphony" of Medical & Drug Integration

### SESSION CHAIR

Ziwei ZHAO, PhD Head of Pharmaceutical Science and Early Clinical Development Department, Roche China Innovation Center

Global Hot Topic of Clinical Pharmacology - 1 Ranchi XU, PhD Head, Clinical Pharmacology, R&D, Biogen

Global Hot Topic of Clinical Pharmacology - 2 Chen ZHAO, PhD Professor, Nanjing Medical University, PI of Jiangsu Clinical Research and Evidence-based Medicine Center

### Panel Discussion

INVITED PANELISTS Prof. Haiyan LI Director of Drug Clinical Trial Institution, Peking University Third Hospital, Chief Physician of Cardiovascular Medicine

Pei HU, MD, PhD Founder, Beijing Lingchu

Jing ZHANG, MD, PhD Professor of Clinical Pharmacology, Deputy Director, Institute of Antibiotics, Huashan Hospital, Fudan University

Yuyan JIN, PhD SVP, Head of Non-Clinical Development, Shanghai Sanegene Bio

Kai SHEN, PhD Head of Clinical Pharmacology Department, Jiangsu Hengrui Pharmaceutical Co., LTD

Xiao ZHU, PhD Young Researcher, Department of Clinical Pharmacy and Pharmacy Management, School of Pharmacy, Fudan University

Xiaojie WU, PhD Deputy Director of Phase I Clinical Research Center, Huashan Hospital, Fudan University

Jing NIE, PhD Head of Clinical Pharmacology Team, Heyu Biomedical Technology Co., LTD

ICH Day	СН
Educational Works	shop 💿 T
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	e III
Drug Clinical Development	
Patient Centered Clinical and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Med	licines
Non-clinical & Anima	al Test
Medical Writing ar Publication	nd 📋
Pediatric Drug Development Foru	ım 📎
Hot Topics	-

THEME LEAD

Ning XU, MD, PhD Executive Vice President, Head of Clinical Development and Regulatory Affairs, Zai Lab

Liping ZHOU Senior Director, QA, MSD R&D (China) Co., Ltd

**Shuting LI** Vice President Jimin Cancer Hospital affiliated to Anhui Medical University Veronica XIA Vice President, China GM, Labcorp Drug Development

Amy JIANG Head of Quality Office, Harbour Biomed

Yang LIN Director of Department of Pharmacy, Director of GCP, Head of Phase I Study Beijing Anzhen Hospital

Jing ZHANG, PhD Deputy Head of Antibiotics Institute, Head of Phase I center Fudan University Affiliated Huashan Hospital

Session 0301-A	December 10, 2022					
08:30-10:00	Effectively Promote the Transformation of Target Patients into Subjects by Multiple Dimensions and Channels					
	SESSION CHAIR					
	Shuting LI	a that a ffiliant at the Analysis Mandiana Libra				
	Vice president of Jimin Cancer Hos	pital affiliated to Annul Medical Uni	/ersity			
	In recent years, clinical research on	new drugs in China has developed	rapidly, but it still faces great challenges i	in which subject recruitment		
	is the key to the rapid development of trials. It is reported that 85% to 95% of the reasons for the delay of clinical trials are the failure to					
	recruit qualified subjects as planned. Therefore, how to successfully convert target patients into subjects is an important problem that the					
	whole industry needs to address.					
		In order to discuss the solution to the subject recruitment, the speaker has done a survey among the colleagues, and the results will be				
	analyzed and summarized. The purpose of the survey is to study the reason of the problems andraise the investigators' awareness of clinical trial, andget through the recruitmentbottleneck to success.					
		In Post-epidemic (COVID-19) Era, Patient Education Will be the Better Approach to Solve Problems That Exist in Clinical Trials				
	Kun SONG					
	VP, Pharmaron(Chengdu) Clinical Service Co.,Ltd					
	Digital Technology Facilitates Patient Education and Recruitment					
	Man HE					
	B2B Department Director, Taimei Technology					
	Benevolence to Patients, Antecedence to Missions					
	Joeann FAN					
	Director of Site management, RDB,	Bayer Health Care Co.Ltd.				
	Panel Discussion: How to enhance the i	roles and responsibilities of each party i	n industry, working together to overcome the	e recruitment challenges		
	Moderator	Invited Panelists				
	George GUO	Xu CAO	Yu CHEN			
	Chief Medical Officer, Hinova	Clinical Project Leader, Sanofi	Senior Director, Shenzhen Microchip			
	Pharmaceuticals Inc.	R&D Center Greater China				

		Centered Clinical Op	erations and Quality I	Management
ucational Workshop	Session 0302-A	A   December 10, 2022	10	1216
ening Plenary	10:30-12:00	Win-win Collaboration of Clinical Oper	ations	
obal Regulatory		Session Chair Invited		
wnhall ina Regulatory ecial Session		Initiate Process Optimization and Strengthe Speaker Invited Risk-based Center Monitoring	n Communication and Collaboration	
gulatory Science		Speaker Inivted Panel Discussion: Integrated and Efficient M	anagement based on Data Flow from Design	
ug Clinical velopment		INVITED PANELISTS Simon YU, MD, PhD	Peipei YANG	Mengmeng ZHANG
ent Centered Clinical Operations Quality Management		Director Global Testing Services, China & Japan Labcorp Drug Development	Deputy Director of Clinical Trial Program Management, IQVIA Biotech (China)	Deputy Director, Pharmacovigilance, Taim Medical Technology
nical Needs and al Platform		Confidence and Humility, Trust and Commun <b>Daisy CHEN</b> Business Partner, Human Resource, Janssen	nication Pharmaceutical R&D and Johnson & Johnson (	China External Innovation Team
ta Science				
ostatistics				
& Drug Safety				
: (				
slational Medicines				
clinical & Animal Test				
lical Writing and lication				
iatric Drug elopment Forum				

ICH Day	Patient	Centered Clinical Operations a	nd Quality Management	
Educational Workshop		- A   December 10, 2022		
Opening Plenary	13:30-15:00	The Practice and Explore for DCT in Early Clinical Phase St	udies	
Global Regulatory Townhall		SESSION CO-CHAIRS Jing ZHANG, PhD Deputy Head of Antibiotics Institute, Head of Phase I Center	<b>Veronica XIA</b> Vice President, China GM, Labcorp Drug Development	
China Regulatory Special Session		Fudan University Affiliated Huashan Hospital Drug Development Clinical Trial DCT Management Exploration and	l Prospect	
Regulatory Science		Yifei CHEN Shanghai CDE		
Drug Clinical Development		Case Sharing— Practice for DCT in Early Clinical Development <b>Dr. Jiejing HE</b> Huashan Hospital		
Patient Centered Clinical Operations	Comparison of a Trial Conducted Completely Remotely and a Trial Where Some Visits Require Patients to Come to Sit Laurie Berry, PhD, PMP			
Clinical Needs and Trial Platform		Clinical Operations Strategic Partnership Lead of Information Management COE, Pfizer		
Data Science		Panel Discussion: Discussion on the Clinical Practice and Developn MODERATOR Veronica XIA	nent of DCT in China	
Biostatistics		INVITED PANELISTS Jing ZHANG Deputy Head of Antibiotics Institute, Head of Phase I center, Fudar	n University Affiliated Huashan Hospital	
PV & Drug Safety		Wei ZHANG, PhD China Head of Medical and Clinical Development, Boehringer Ingelheim		
смс 主		Marion MARTIN, PhD Head of Strategy and Technology Innovation, Pfizer R&D China		
Translational Medicines		Jennifer LI VP & China GM, Medidate		
Non-clinical & Animal Test		Kevin LIN		
Medical Writing and Publication		CEO, Shanghai Xincere Med-Tech Inc.		
Pediatric Drug Development Forum				
Hot Topics			2022 DIA China Annual Meeting	

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	s A
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0305-A | December 11, 2022

8:30-10:00

**Emerging Technologies Empowering Clinical Operations – 1: Novel Digital Endpoints** 

### SESSION CHAIR

Connie DAI, PhD Vice President, Strategies and Innovation, HLT

Digital health technology is transforming the drug, device and diagnostics development process. These technologies have the potential to enable innovative trial designs, improve the patient experience, act as recruitment and retention tools, and establish novel end points in clinical studies. This session will focus on the impact of digital health technologies on clinical development operations, as existing clinical endpoints change or novel digital endpoints that could not be measured previously.

Topic TBD Laura PIOPPO EMA

Exploring Digital Endpoints in Neuroscience Haiyan WU, PhD People and Product Lead, PD Data Science, Roche China

Methodological Validation of Novel Digital Endpoints Carrie A NORTHCOTT, PhD Director & Project Lead, Digital Medicine & Translational Imaging, Pfizer Inc

Developing a More Complete Picture of the Patient Experience through an Integrated Approach to eCOA and Sensors CO-PRESENTERS Ben SCHLATKA VP, Digital Biomarkers, Medidata

Paul O'DONOHOE Senior Director, eCOA Product & Science, Medidata

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operat and Quality Management	tions
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicine	
Non-clinical & Animal Tes	
Medical Writing and Publication	
Pediatric Drug Development Forum	<b>N</b>
Hot Topics	

Session 0306-A | December 11, 2022

10:30–12:00 Emerging Technologies Empowering Clinical Operations – 2: Experience and Technical Support of Digital Clinical Trials

### SESSION CHAIR

Weiyi ZHENG

Vice President, Head of Operations, AstraZeneca Global R&D China Center

DCT is a new type of clinical research with patient-centered, decentralized mode and supported by digital technology and platform. Through case summary and practical technical analysis, this special session focuses on how the application of innovative technologies in the process of clinical trials can enable clinical operation, how to support the improvement of patient participation experience, reduce the burden of patients' multiple trips to the research center, so as to improve patient compliance. At the same time, the timeliness and reliability of clinical trial data collection will be further improved to provide path reference for the 2030 transformation goal of clinical trial modernization.

#### DCT Case Studies

Yan MA Director, Clinical Operations, IQVIA

#### Evaluation of Major Digital applications in DCT Gaoyang LI Head of DCT, HLT

Patient Visit Choice (Remote or at Site) - Changing Complexity of Data Collection in Clinical Trials James STREETER Global Vice President, Life Science Customer Success. Oracle

# DCT Challenges in China and Possible Solutions for HHC **Zhemin JIANG**

PPD

### Increase Trial Resiliency through Technologies - Mobile Clinical Solutions Implementation in the APAC Region **Kurt LUMSDEN** Head of Global Operations, GlobalCare Operations, LabCorp

ICH Day	Patient	Centered Clinical Operations and Quality Management	
Educational Workshop		CH. CH	-
Opening Plenary		onal Drug Management & Supply Chain	
Global Regulatory Townhall	8:30-10:00	Internal Management of Investigational Drug - from the Sponsor Perspective: Part 1	
China Regulatory Special Session		SESSION CHAIR Amy JIANG Head of Quality Office, Harbour Biomed	
Regulatory Science	D	Sponsor's Traceable Management System for Investigational Drug Feng HE	
Drug Clinical Development		Head, Clinical Supply Chain, Zai Lab Sponsor's Entrustment Investigational Drug Management	
Patient Centered Clinical Operations and Quality Management		<b>Jin Ll</b> Deputy Manager, GxP Quality, Harbour	
Clinical Needs and Trial Platform		Temperature Management of Investigational Drug <b>Yadan HUO</b> Associate Director, Clinical Operations, Clinical Development, BeiGene(Beijing)Co.,Ltd.	
Data Science		Panel Discussion	
Biostatistics			
PV & Drug Safety			
смс			
Translational Medicines			
Non-clinical & Animal Test			
Medical Writing and Publication			
Pediatric Drug Development Forum			
Hot Topics		2022 DIA China Annual Meet	ing 49

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0302-B | December 10, 2022

10:30-12:00

SESSION CHAIR Winne XU VP, Head of Greater China, Global Clinical Operations, BeiGene	
Production and Management of Investigational Vaccines Gang ZENG	
Senior Medical Director, Beijing Sinovac Biological Products Co	o., LTD
Preparation and Management of CAR-T in Clinical Trials Weilin HUANG	
Clinical Operations, Nanjing Legend	
Countermeasures for the Management of Investigational Drug CO-PRESENTERS	under Pandemic
Yadan HUO Associate Director, Clinical Operations, Clinical Development, I	BeiGene
<b>Na SONG</b> Deputy Director, Clinical Supply Chain, BeiGene	

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$( \mathbf{G} )$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0303-B | December 10, 2022

13:30-15:00	Traceable Transportation of Investigational Drug from Sponsor to Clin	ical Site
	SESSION CHAIR	Cul
	Yufeng CAO	
	Founder of Kagan	
	Regulation for the Management of Investigational Drug	
	Lijun ZHU	
	Director, Quality, Kagan	
	Traceable Transportation Process Management System for Investigational Drug Nan ZHANG	
	General Manager, China Clinical Trial, Thermo Fisher	
	Application and Regulation for Import and Export of Investigational Drug Xinming HU	
	Assistant to General Manager, Beijing Yizhuang International Biological Reager	nt Logistics Center Co., LTD.
	Panel Discussion	
	INVITED PANELISTS	
	Yang LIN Directory of Donortheant of Dharmoon, Directory of CCD, Hood of Dhare I Study, Di	
	Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Be	eijing Anznen Hospital
	Feng HE	
	Head, Clinical Supply Chain, Zai Lab	

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Centralized Management of Investigational Drug in Clinical Site

Session 0304-B | December 10, 2022

16:00-17:30

SESSION CHAIR Yang LIN Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Beijing Anzhen Hospital Management Model of Investigational Drug in European and American Speaker Invited Centralization and Intelligent Management of Investigational Drug Yang LIN Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Beijing Anzhen Hospital How to Choose the Clinical Site from Investigational Drug Management Perspective - from Sponsor Perspective April HUANG Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution Executive Director of Phase I Clinical Trial Laboratory		
Speaker Invited Centralization and Intelligent Management of Investigational Drug Yang LIN Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Beijing Anzhen Hospital How to Choose the Clinical Site from Investigational Drug Management Perspective - from Sponsor Perspective April HUANG Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution	Yang LIN	hen Hos <mark>pital</mark>
Yang LIN Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Beijing Anzhen Hospital How to Choose the Clinical Site from Investigational Drug Management Perspective - from Sponsor Perspective April HUANG Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution		
Director of Department of Pharmacy, Director of GCP, Head of Phase I Study, Beijing Anzhen Hospital How to Choose the Clinical Site from Investigational Drug Management Perspective - from Sponsor Perspective April HUANG Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution		
April HUANG Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution	-	hen Hospital
Executive Director, Head of Clinical Operations, InnoCare Pharma Panel Discussion INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution		n Sponsor Perspective
INVITED PANELISTS Bo YU Huan ZHOU Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution		
Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital Affiliated to Bengbu Medical College) Director of the National Drug Clinical Trial Institution	INVITED PANELISTS	
	Deputy Director, The First Affiliated Hospital of Bengbu Medical College (Cancer Hospital the National Drug Clinical Trial Institution	Affiliated to Bengbu Medical College) Director of

CH Day	Patient	Centered Clinical Operations and Quality Management
ducational Workshop	Clinical Qu	ality Management
opening Plenary		C   December 10, 2022
ilobal Regulatory	13:30-15:00	Jointly Build a Quality Management System for Clinical Trials - Part 1
		SESSION CO-CHAIRS       Ying GONG         Vanfei LIU       Ying GONG         Director, GCP Center, Fu Dan University Shanghai Cancer Center       Head of Clinical Development Quality, Pfizer China R&D Center
		All stakeholders involved in clinical trial quality - Sponsors, Institutions (or Hospitals), Regulatory Agencies, and Third-party Service Providers (or vendors) to form an interoperable Quality Management System (One QMS); following unified quality management standards, regularly sharing quality management reports from both sides, and exchanging action plans and results to prevent risks. Finally, to develop a shared,
rug Clinical evelopment		trusting community by building 'forward-looking' conversations.
ient Centered Clinical Operations		Regulatory Expectations for Quality Management in Clinical Trials and Interpretation of the Key Points in the 2021 New Edition of Inspection Points CFDI Speaker Invited
nical Needs and al Platform		The Improvement of Co-construction in the Clinical Trials Quality Management System - from the Perspective of Hospital Management <b>Yanfei LIU</b> Director, GCP Center, Fu Dan University Shanghai Cancer Center
a Science		Panel Discussion
statistics	Session 0304-	C, December 10, 2022
	16:00-17:30	Jointly Build a Quality Management System for Clinical Trials - Part 2
Drug Safety		SESSION CO-CHAIRS
		Ying GONG Head of Clinical Development Quality, Pfizer China R&D Center How to Build a Quality Management System from the Perspective of the Sponsor Jing ZHANG
ational Medicines		Quality Management Lead, Pfizer China R&D Center
inical & Animal Test		Introduction of the Vendors' Quality Management System <b>Yuyan ZHU</b> VP, Head of Quality Management, Tigermed Consulting Ltd
cal Writing and cation		Panel Discussion INVITED PANELISTS
atric Drug elopment Forum		Yifei CHENJun YANGuoqing YANGShanghai Center for Drug Evaluation and InspectionGCP Officer, GoBroad Healthcare GroupQA Executive Director, Henlius
Topics		2022 DIA China Annual Meeting 53

\_

ICH Day	ІСН	Patient	<b>Centered Clinical Operations and Quality Management</b>	
Educational Workshop	$\overline{\bigcirc}$	Session 0305-C	December 11, 2022	-
Opening Plenary		8:30-10:00	Quality by Design: Exploring the Opportunities and Challenges of GCP Quality from the Perspective of GCP Site	Inspection
Global Regulatory Townhall			SESSION CHAIR Sean XU Xiao Ming Tong Da	
China Regulatory Special Session			The Orientation of Quality Management - Agency Perspective CFDI Speaker Invited	
Regulatory Science			Innovative Exploration of Site Quality Management Yifeng SHEN	
Drug Clinical Development			Director of drug Clinical Trial Institution Office of Shanghai Mental Health Center The Practice and Thinking of How Sponsor to Assist the Site Quality	
Patient Centered Clinical Operation and Quality Management			Jennifer HUANG MSD	
Clinical Needs and Trial Platform		Session 0306-C		
Data Science		10:30-12:00	Quality by Design: Reflection from Inspection Findings and Possible Solutions         SESSION CO-CHAIRS         CFDI Session Chair Invited	
Biostatistics			Liping ZHOU QA Head, Asia Pacific, MRL	
PV & Drug Safety			Review of Important Findings in GCP Verification and Industry Thinking CFDI Speaker Invited	
смс			Panel Discussion INVITED PANELISTS	
Translational Medicines			Hannah CHEN	
Non-clinical & Animal Test			Jifang GONG	
			Yanping LIU	
Medical Writing and Publication			Wei ZHANG, PhD	
Pediatric Drug Development Forum				
Hot Topics			2022 DIA China Annual Me	eting 54

ICH Day	ІСН
Educational Workshop	$\overline{\bigcirc}$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	s 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

### **Clinical Needs and Trial Platform**

THEME LEAD

Ning LI, MD, PhD Chief Physician, Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences

### Binyun QIAN, MD, PhD

Director, Shanghai Clinical Research Promotion and Development Center

Chief Physician, Department of Digestive Oncology, Peking University Cancer Hospital Chairman of Ethics Committee of Peking University Cancer Hospital

Jessica LIU Head of M&A Department, Tigermed

Session 0401-A	A   December 10, 2022
8:30-10:00	Overseas Clinical Trial Experience Sharing
	SESSION CHAIR
	Jessica LIU
	Head of M&A Department, Tigermed
	Overcoming Barriers in Clinical Trial Activation in Large US Academic Centers
	Andrea WANG-GILLAM MD, PhD
	Chief Medical Officer, Jacobio (US) Pharmaceuticals, Inc
	Japan's Academic Collaborative Programs on Drug Development
	Kenichi NAKAMURA, MD PhD
	Director, Department of International Clinical Development/
	Chief Management Officer, Clinical Research Support Office,
	National Cancer Center Hospital JAPAN
	Director, JCOG Operations Office
	Best Practice Sharing on Clinical Research Center Management from 4 Continents in the World
	Natalie WILSON
	UK Business Development Manager, National Institute for Health Research, UK
	Yil-Seob LEE, MD, PhD
	Director, CHA Global Clinical Trials Center
	CHA Bundang Medical Center, Korea
	Ricardo Sobhie DIAZ, MD, PhD
	Director, Retrovirology Laboratory, Federal Medical School of São Paulo, Brazil
	Nyeleti Bicky MTHOMBENI
	Chairperson, South African Clinical Research Association
	Operations Director, OnQ Research

ICH Day	ІСН
Educational Workshop	<b>()</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

### **Clinical Needs and Trial Platform**

Session 0402-A | December 10, 2022

10:30–12:00 Standardization of IIT Study

Session Chair Invited

In order to standardize the management of clinical research, improve the quality of clinical research and promote the healthy development of clinical research, the National Health Commission (NHC) issued the Management Of Investigator-initiated Clinical Research in Medical and Health Institutions.

It will be implemented on a pilot basis in Beijing, Shanghai, Guangdong and Hainan provinces from October 1, 2021. IIT research is often carried out with the joint participation of enterprises. How can IIT be actively and steadily promoted, and the management of investigatorinitiated trial carried out by health institutions is worthy of joint exploration and discussion by experts from hospitals and industry.

Reflections on Mutual Recognition of IIT Ethics **Qi LU** Chief of Ethics Officer, Shanghai Jiaotong University School of Medicine Renji Hospital

#### The Role and Value Of IIT: System Building and Study Innovation

Qingwei ZHAO

Director of Department of Clinical Pharmacy, The First Affiliated Hospital of Zhejiang University School of Medicine/Director of Clinical Pharmacy Research Center/Director of Office of National Drug Clinical Trial Institution

Standardization of Cooperation Model in IIT Study Naiging ZHAO

CSO, Caidya Biopharmaceutical Co., Ltd

Panel Discussion: How to Define the Scope of IIT Study? INVITED PANELISTS Xingli WANG, PhD

Tong GUO, PhD

Naiqing ZHAO

ducational Workshop	Session 0403-A	A   December 10, 2022
	13:30-15:00	Ethics Regulation
lobal Regulatory ownhall		SESSION CHAIR Jie LI Chief Physician, Department of Digestive Oncology, Peking University Cancer Hospital
ina Regulatory ecial Session		Chairman of Ethics Committee of Peking University Cancer Hospital
gulatory Science		The Impact and Requirements on Clinical Trial and Ethical Review after the Enactment and Implementation of the Personal Information Protection Law ian YANG, JD
ug Clinical		Associate Researcher, Health Law Research Center, Peking University Health Science Center
ient Centered Clinical Operations		New Interpretation of "Ethical Review of Life Sciences and Biomedical Clinical Trial That Involving Human Beings" <b>Chieko Kurihara</b> Bio-ethics Expert, Japan
nical Needs and		Panel Discussion
	Session 0404-A	A   December 10, 2022
nta Science	16:00-17:30	Ethics New Technology
ostatistics		SESSION CHAIR Jie LI Chief Physician, Department of Digestive Oncology, Peking University Cancer Hospital
& Drug Safety		Chairman of Ethics Committee of Peking University Cancer Hospital
c 主		Ethical Considerations for Clinical Development of CAR-T Drugs <b>Jifang GONG, MD, PhD</b> Deputy chief physician, Department of Digestive Oncology, Peking University Cancer Hospital
nslational Medicines		Brain-machine Interface
n-clinical & Animal Test		Xueqin WANG, MD, PhD Member of Ethics Committee and Office Director of Peking University Sixth Hospita
dical Writing and blication		Panel Discussion INVITED PANELIST Lei LIU

ICH Day	ICH
Educational Workshop	$\overline{\bigcirc}$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

### **Clinical Needs and Trial Platform**

Session 0401-B | December 10, 2022

8:30–10:00 The Implementation and Difficulties in Establishment and Development of Research Hospital

### SESSION CHAIR

Jing HE, MD, PhD SVP, Head of China R&D Global Oncology R&D, Astrazeneca

The establishment of research ward hospital is an innovative attempt to solve the problem of clinical research resources being occupied by large hospitals and to improve the level and efficiency of clinical research in China. In 2020, Beijing will take the lead in selecting the first batch of qualified Research ward hospitals, now has developed the third batch of 30 hospitals in total, Shanghai and other places are also actively promoting research ward, and even more cities will promote the 14th five-year development focus on the establishment of research hospital.

How is the research ward hospital implemented today? Does it solve the problem of insufficient research resources? Is it sustainable? What is the international experience of research hospitals worth learning from? The sector will invite industry experts from the strategic layout, practical effect, international experience and other perspectives, in-depth discussion and sharing.

Research Ward Hospital's Layout, Implementation, Feedback and Key Points Analysis Speaker Invited

Operation Model, Development Direction and Expected Effect of Research Hospital **Chouwen ZHU** Director of Shanghai Clinical Research Center

Experience Sharing and Localization of International Clinical Research Centers **Yu TANG, MD, PhD** Head of GCP Central Office, Cancer Hospital, Chinese Academy of Medical Sciences

Panel Discussion

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

### **Clinical Needs and Trial Platform**

Session 0402-B | December 10, 2022

10:30–12:00 "Not" Clinical Value Driven Clinical Study

#### SESSION CHAIR Wei ZHANG, PhD

VP, Regional Head of Biometrics and Data Management, Asia/MENA, Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.

Since November 19, 2021, China officially issued and implemented the Clinical Value-Oriented Guiding Principles for Clinical Research and Development of Anti-tumor drugs, "clinical value-oriented" and "patient-centered" have become the hottest concepts and topics, and various explanations emerge in an endless stream. So in the pharmaceutical research and development, how to embody the patientcentered? Who is the leading opinion on the value of clinical research? Who has the final say on clinical value? Front-line clinical doctors and patients should have the best say. What is needed and what is not, listen to what they say about clinical value and what they see as "Not" clinical value Driven drug R&D.

What Does "Not" Clinical Value Driven Clinical Study Look Like?

Dawei WU Ethics Director, GCP Center, Cancer Hospital, Chinese Academy of Medical Sciences

Innovation and R&D Help Increase the Value of the Company Cong XU Executive Director, Eli Lilly Asia Ventures

What Kind of Clinical Research is Most Valuable to Patients? **Weiling ZHENG** Paraxel

Conflict and Compromise between Clinical Value and Commercial Value

Huiyao HUANG Academic Secretary, GCP Center, Cancer Hospital, Chinese Academy of Medical Sciences

ICH Day	ІСН
Educational Workshop	<b>(</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

### THEME LEAD

Daniel LIU, PhD Chief Scientific Officer, Clinical Service Center

Hualong SUN, PhD General Manager, Meta Clinical Technology Co. Ltd

#### Session 0501, December 10, 2022

08:30-10:00

Regulatory Requirements and Practice of Direct Data Capture (DDC)

### SESSION CHAIR

Hualong SUN, PhD General Manager, Meta Clinical Technology Co. Ltd

At present, the data of drug clinical trials are mainly collected by Electronic Data Capture system (EDC), and most of the data need to be transcribed into the EDC system from the medical records of Investigational hospitals by the Investigators or clinical research coordinators (CRC), which not only affects the efficiency but also may have the occurrence of transcription errors. Whether to collect data directly from medical records of investigational hospitals through system tools, whether there are corresponding regulatory requirements, and the current progress at home and abroad will be shared and discussed in this topic.

Executive Director, Head of Clinical Data Monitoring & Management, Pfizer

### Regulatory Requirements and Opportunities for Clinical Research of Director Data Capture Hualong SUN, PhD

Anita SHEN

General Manager, Meta Clinical Co. Ltd

#### Practice and Case study of Director Data Capture

Wei SHI Chief Technical Officer, Clinical Trials Express (Shanghai) Co., Ltd.

### Exploration and Practice of Data Capture Information Management for Drug Clinical Trials **Hua ZHANG**

Director of Drug Clinical Trial Institute, The First Affiliated Hospital of Soochow University

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation: and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

Session 0502 | December 10, 2022

10:30-12:00 Source Data Management in Clinical Trials

### SESSION CHAIR

Daniel LIU, PhD Chief Scientific Officer, Clinical Service Center

Regulatory managements of the source data management in clinical trials play a key role in the compliance of data quality and integrity. Based on GCP principles, every data input in the CRF should be conformant and integrity with source data and documents, ensuring the compliance of source verification, attribution and rebuildability. With development of e-clinical technology, an e-source data is becoming a trend in clinical trials. Thus, e-clinical data should be compliant with the GCP and regulatory requirements. This session is focusing on discussions and interactions regarding the definition and types of source data and regulatory expectations. The e-source management and standards is explored as well

### Global Standards of Clinical Data Quality in Clinical Trials **Zhijun WEI**

Head of Clinical Data Standardization and Innovation, Novartis

#### Management of Source Data Life Cycle in Clinical Trials

Jian ZHANG, MD Chief Physician, Director of Phase I Ward/Medical Oncology of Tumor Hospital Affiliated to Fudan University

#### Regulatory Expectations of e-Clinical System in Compliance of e-source Data Integrity

Daniel LIU, PhD Chief Scientific Officer, Clinical Service Center

### Panel Discussion: Good Practice of Source Data Regulations in Clinical Trials

Above Speakers and Invited Panelist Yuqiu YANG General Manager, Riehen

ICH Day	ІСН
Educational Workshop	
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

#### Session 0503 | December 10, 2022

13:30–15:00 Data Anonymization and Data Privacy

#### SESSION CHAIR Zhenglong TIAN

Chief Data Officer, Gobroad Healthcare

The 21st century alone has created 98% of all data that humankind has piled up since we started writing history. Big data makes it possible for us know more about the world. Data-driven methodology could be a bright future to accelerate drug discovery and development. However, it is critical to balance the data publicity and data privacy in order to well utilize the data information. Hence, data anonymization become more and more important. The Privacy Rule standards which address the use and disclosure of individuals' health information (known as "protected health information") by entities subject to the Privacy Rule have been mentioned in HIPAA. Also, the criticalness of anonymization has been mentioned in EMA policy 0070 and GDPR. However, there are no universally agreed approaches about how to properly perform data anonymization. In this section, some practices will be discussed in healthcare and clinical industry regarding data anonymization to ensure data privacy.

#### "Practice of Anonymization of Both Electronic and Non-electronic Source Data in Remote Monitoring" Yuan HAO

Product Director of Intelligent Clinical Trial Solutions, Hlife Tech

Risk Assessment Post Data Anonymization Joey WANG Deputy General Manager, Meta Clinical

### Best Practice for Privacy and Cybersecurity Compliance in Medical and Health Industry **Bruce ZHANG** Partner, Ernst & Young (China) Enterprise Consulting Co., LTD

		cience
tional Workshop	Session 0504	December 10, 2022
ary	16:00-17:30	Real World Data Quality Evaluation
ry 🤅		SESSION CHAIR Chen YAO, PhD Director, Department of Medical Statistics, Peking University First Hospital
		Academic institutions, hospitals and CROS were invited to discuss the quality evaluation and data governance of regional health big data. Discuss the significance of CDISCS-eCRF development to ensure the integrity of hospital real world data. And based on the risk of quality management concept to establish data quality management system construction thinking.
	<b>O</b>	Improving Real-world Data Integrity Using Electronic Data Capture based on CDISC-CRF Data
(		<b>Xiaoxia PENG</b> Director, Center for Clinical Epidemiology, Beijing Children's Hospital, National Center for Children's Health
		Quality Evaluation and Data Governance of Regional Health Big Data
ons		Zhike LIU Associate Professor, School of Public Health, Peking University
		Considerations for Quality Management of Real-World Data Julia ZHU VP, Head of QA Department, Tigermed Group
	Session 0505	
	08:30-10:00	Clinical Data Talent Development
+		SESSION CHAIR
Θ		Anita SHEN Executive Director, Head of Clinical Data Monitoring & Management, Pfizer
ŀ		With the help of policies and capital, China's pharmaceutical industry is accelerating development, and the demand for pharmaceutical R&L talents is increasing sharply. In the face of unprecedented opportunities and challenges, data management talents are the ability cornerstor and core competition
cines		What is the force? It is hoped that initial ideas on the skill elements and grade considerations of data talent will be shared to facilitate
		industry consensus. At the same time, CRO is also an indispensable force in pharmaceutical research and development. How to continuously and effectively cultivate data management talents and create a funny data management team in the rapidly changing external environment Team? Senior team leaders will share valuable experiences and challenges.
		Finally, the data management industry has quietly changed under the impact of new ideas and technologies. The future is here. Are you ready? In this session, we will explain the new trends in the data management industry Potential, looking forward to the future talent capacity of the new demand.
N.	Ø	• •
		2022 DIA China Annual Meeting 6

We is a large of the

ICH Day	ІСН
Educational Workshop	Ð
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

#### Session 0506, December 11, 2022

10:30–12:00 How to Ensure Data Quality through Cross Functional Collaboration: Case Sharing

### SESSION CHAIR

Charles YAN, PhD Vice President, Data Science Center, Hengrui

Ensuring the data quality is always on the critical path to success in clinical trials. There are multiple functions and personnel involved in the procedure from data collection to analysis, which makes cross functional

Good Cross-Functional Collaboration in Scientific eCRF Design Lin BIE Assistant Director, Data Management, Hengrui

### Cross-Functional Collaboration in Data Clean **Di ZONG**

Senior Manager, Clinical Operation, Hengrui

#### How to Control Data Quality to Meet Statistical Analysis and Data Submission Needs

Chunxia CHEN Associate Director, Statistics, Hengrui

#### Panel Discussion

INVITED PANELISTS

Yue ZHANG General Manager, Data Center, Henlius

#### Wei ZHANG

Head of Data Management, GSK

ICH Day	ІСН
Educational Workshop	<b>()</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

THEME LEAD Feng CHEN, PhD Professor, Dean, School of Public Health, Nanjing Medical University

Jielai XIA, PhD Professor, Xi 'an Air Force Military Medical University

Michael LEE, PhD Vice President, Head of Biometrics, Harbour BioMed

Session 0601 | December 10, 2022

Wei ZHANG, PhD VP, Regional Head of Biometrics and Data Management, Asia/MENA Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.

Lihong HUANG, PhD Department of Biostatistics, Zhongshan Hospital, Fudan University

Tony GUO, PhD Global Head of Statistics and Data Science, VP, BeiGene

08:30-10:00 On Rare Disease Drug Development Pathway and Clinical Study Designs – Case Studies

#### SESSION CO-CHAIRS

Michael LEE, PhD Senior VP, Head of Biometrics, Harbour BioMed, Inc. Xiaoni LIU, PhD Biostatistics China Site Head, Novartis

Unmet medical need in rare disease is getting more and more attention in the past years. There are unique challenges in rare disease drug development. CDE and FDA recently released guidance documents specific for rare disease drug development and regulatory pathway, such as CDE Guidance on Technical Aspects in Rare Disease Drug Development and FDA Rare Diseases: Common Issues in Drug Development. Speakers in this session will share their experience and thoughts on this topic.

Basket Design with Bayesian Hierarchical Model for Rare Diseases Tong ZHU, PhD

Principal Statistician, Novartis

Case Examples for Rare Diseases: Bayesian Methods and n-of-1 Design **Jun DONG, PhD** Head of Biostatistics and Programming, Amgen China

Epidemiological Research for Rare Disease using National Insurance Data **Pei GAO, PhD** Professor, School of Public Health, Peking University

ICH Day	ІСН	
Educational Workshop		
Opening Plenary		
Global Regulatory Townhall	$( \mathbf{G} )$	
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operations and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
смс		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

Session 0602 | December 10, 2022

10:30–12:00 Practicing ICH E17 for Simultaneous Global New Drug Development & Registration

#### SESSION CO-CHAIRS

Yabing MAI, PhD Head of Biostatistics and Data Science, Boehringer Ingelheim Robert LUO Pfizer

With the globalization of drug research and development, multi-regional clinical trial (MRCT) has attracted increasing attention. The implementation of MRCT can speed up the simultaneous development of new drugs and maintain the same level of scientific rigor in trial design when trial results are registered for review by multiple regulatory agencies. At the same time, it can optimize valuable patient resources and reduce unnecessary research and development costs. ICH E17 will better improve the acceptability of MRCT regulatory submissions worldwide by addressing specific issues and general principles of MRCT planning and design.

A review of the industry practice in the past few years shows that While China's participation in the global REGISTRATION of synchronized R&D has achieved success, it also faces many challenges. Therefore, this unit will focus on how to identify and address many challenges in the global simultaneous development and registration of new drugs through better practice of the ICH E17 guidelines. Through professional consideration and typical case sharing from experts in different fields on some key issues (such as ethnic consistency evaluation, regional sample size allocation, design and analysis method selection, etc.), some guidance can be provided for overcoming these challenges in practice and achieving true synchronization.

In-depth Experience in MRCT & E17 Bruce BINKOWITIZ Biometrics VP, Arcutis US

#### MRCT & E17 Regulatory Perspective

Yaping WANG, PhD Former FDA Reviewer

#### MNC Perspective

Chao ZHU, PhD Head of Statistics and Programming, Lilly

### Panel Discussion

INVITED PANELISTS Feng CHEN, PhD Professor, School of Public Health, Nanjing Medical University

#### Yan HOU, PhD

Associate Researcher, Department of Biostatistics, Peking University Health Science Center

ICH Day	ICH
Educational Workshop	<b>()</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

### **Biostatistics**

Session 0603 | December 10, 2022

13:30-15:00	Design and Considerations in Vaccine Trials		
	SESSION CO-CHAIRS		
	Prof. Yang Huan Former China CDE	Jeannie QIU, PhD Head of Biometrics and Data Science, FosunPharma Global R&D Center	
	encountered many specific questions up of primary study endpoints and s	of vaccine studies and the development of novel vaccine technologies in recent years, investigators hav s in the vaccine trials, including registration strategy and trial design to provide sufficient evidence, set ample sizes, and considerations of statistical analysis methods and Estimand. We hope to better guide uality vaccine trials by discussion and communication with vaccine experts.	
	Review of Clinical Trial Design of New Jielai XIA, PhD Professor, Xi 'an Air Force Military Me		
	Design and Considerations of COVID-19 Vaccine Trials Jingxin LI, PhD Researcher, Jiangsu CDC		
	Challenges in Vaccine Clinical Design Jie SHAO, PhD General Manager, Clinical Center of Z		
	Methods for Evaluation of Medium an <b>Zhiwei JIANG</b> General Manager, Beijing Kontrico St	nd Long-term Protective Efficacy in Vaccine Trials	

ICH Day	ІСН
Educational Workshop	$\overline{\bigcirc}$
Opening Plenary	
Global Regulatory Townhall	$( \mathbf{G} )$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0604 | December 10, 2022

16:00–17:30 Trial Design, Data Collection and Statistical Analysis for Decentralized Clinical Trials (DCTs)

#### SESSION CHAIR Chao ZHU, PhD

Head of Statistics and Programming, Lilly China

In recent years, especially since the start of COVID-19 pandemic, decentralized clinical trials (DCTs) have attracted extensive attention. Some hybrid DCTs in combination with conventional site-based clinical trials, even full-mode DCTs, are increasingly used in drug development. From this perspective, this session will provide some thoughts on DCT trial design, data collection and statistical analysis and discuss issues and possible solutions when implementing DCTs in China.

Decentralized Clinical Trials (DCT): Considerations in Protocol Design Shuyan CHENG Digital Trials Asia Lead, Boehringer Ingelheim

#### Decentralized Clinical Trials (DCT): Data Considerations Wei ZHANG

Head of Data Management, GSK China

Decentralized Clinical Trials (DCT): Statistical Considerations Dong GUO Head of Statistical Programming, Lilly China

#### Panel Discussion

ICH Day	ІСН
Educational Workshop	<b>(</b> )
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0605 | December 11, 2022

8:30-10:00 Application and Challenge of Artificial Intelligence in the Whole Lifecycle of Drug Development

#### SESSION CHAIR

Yang ZHAO, PhD Dean, Department of Biostatistics, Nanjing Medical University

Although Artificial intelligence (AI) methods such as machine learning are rarely used in the analysis of registered confirmatory clinical trial data, they are used in drug molecular discovery, clinical trial operation, real-world research and health economics evaluation

Al methods have been used more and more widely. These methods speed up the process of drug research, reduce the cost, make full use of various resources, and contribute to the quality of drugs and research itself. Experts from industry and academia will share the methods and applications of ARTIFICIAL intelligence in drug research and development, as well as the challenges it faces.

#### A Review of Machine Learning and Artificial intelligence Applications in the Pharmaceutical Industry Haoda FU, PhD

Vice President, Head of Machine Learning and Artificial Intelligence Enterprise, Lilly

Machine Learning Algorithms based on Biomarkers Empowered Drug Development Decisions Cong ZHANG Novartis

Machine Learning, Causal Inference and Drug Clinical Trials Yang ZHAO, PhD Dean, Department of Biostatistics, Nanjing Medical University

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$( \mathbf{G} )$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0606 | December 11, 2022

10:30–12:00 Guidance on Risk Management: From Theory to Practical Implementation

#### SESSION CHAIR

Guohua (James) PAN Senior Director, Janssen China R&D

This session will provide perspectives about the statistical guideline on centralized monitoring and share experience from the pharmaceutical industry about risk management in China and globally ranging from data management practice to statistical considerations. The session will focus on some current best practices as well as covering some novel requirements such as Quality Tolerance Limits as required by ICH E6 R2.

Centralized Monitoring and Associated Statistical Considerations **Zhenglong TIAN** Vice President, GoBroad Healthcare Group

Implementation of a Statistical Surveillance Processes in Clinical Operation Sina Djali Senior Director, Janssen China R&D

Quality Risk Tolerability Limit (QTL): Quantitative Tools Used in Dynamic Monitoring and Quality Assurance in Ongoing Trials **Tian LIU** 

Associate Director, Biostatistics, Novartis

## Strategies and Implementation of Risk-based Quality Management in China **Pamela CHEN**

Vice President, Tigermed

ICH Day	ICH	
Educational Workshop	0	
Opening Plenary		1
Global Regulatory Townhall		I
China Regulatory Special Session		
Regulatory Science		-
Drug Clinical Development		-
Patient Centered Clinical Operation and Quality Management	s A	
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

### THEME LEAD

Yuan MENG Head of Medical Office R&D, I-Mab Biopharma

Conny MO Founder, Medical Safety Advisor, Beijing XAJK Medical Technology, Co., Ltd.

Vera LIANG Drug Safety Unit Regional Head, Asia Pacific, Worldwide Safety, Pfizer Howe LI, MD, PhD Chairman and CEO, Deltamed Co. Ltd

Xiaojing ZHAN Vice President, Drug Safety, Junshi

#### Zheng JIAO Director of Pharmacy Department, Deputy Director of GCP Center Chest Hospital Affiliated to Shanghai Jiaotong University

#### Session 0701 | December 10, 2022

#### 08:30-10:00 Safety Considerations in Clinical Development

#### SESSION CHAIR

Vera LIANG

Drug Safety Unit Regional Head, Asia Pacific, Worldwide Safety, Pfizer

With the rapid growth of drug innovation, the number and complexity of clinical trials have increased significantly. Meanwhile, pharmacovigilance has become an area of focus in the pre-marketing space given the elevated attention to ensure safety of the patients who are exposed to the biopharma products, which are still in the process of investigation. Biopharmaceutical innovators, regulators and healthcare professionals have been collaborating to develop guidelines, and to advance the safety science, which drive enhanced pharmacovigilance and safety risk management earlier in drug development. The pharmaceutical industry here in China has been evolving and adapting quickly to the changes to ensure the upmost patient safety.

This session aims to provide an overview of required safety monitoring activities during clinical trials. We are honored to have the experts from the health authority and pharmaceutical industry to share their insight and experience on several topics that are considered 'hot' in today's environment.

Pharmacovigilance in Clinical Development – An Update from the Health Authority CDE Speaker Invited

#### Executing an Effective Safety Monitoring in Clinical Development

Xiujing KOU, MD, PhD

Site Head, Product Development Safety, Roche Product Development China

#### Management of Suspected, Unexpected and Serious Adverse Reaction (SUSAR) Reports and Special Safety Concerns

**Fangfang SHI, MD** Senior Director, Therapeutic Area Head Product Safety Surveillance & Reporting, Worldwide Safety, Pfizer China R&D Center

#### Panel Discussion

- Clinical safety review for marketing applications

- Practical aspects of pre-approval risk assessment
- SUSAR reporting
- Safety communication during pre-approval

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	Ø
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	X
Hot Topics	

Session 0702 | December 10, 2022

10:30-12:00Post Approval PV

#### SESSION CHAIR

Li ZHANG, MD, PhD Chief pharmacist, Beijing University of Chinese Medicine Oriental Hospital

Post-marketing drug safety monitoring is the core content of pharmacovigilance activities to realize the supervision of drug life-cycle and optimize the related clinical decisions. In this session, pharmacovigilance and related experts from home and abroad are invited to discuss issues including global pharmacovigilance development trend, pharmacovigilance practice experience of medical institutions and enterprises, medical insurance payment and comprehensive drug evaluation to further improve the safety risk management level of postmarketing drug and ensure public safety use.

Modern Methods of Pharmacovigilance - a Global Perspective Niklas Norén Chief Science Officer, Uppsala Monitoring Centre

Construction and Practice of Phamacovigilance System of HCP Xiaole ZHANG President of Beijing Yaodun Public Welfare Foundation

Intelligent Automation and Real World Surveillance for Safety Andrew BATE VP & Head, Safety Innovation & Analytics, Global Safety, GSK

#### DRG Payment and Drug Overall evaluation

Lili WANG

Researcher, Center for Health Policy and Technology Evaluation, Peking University Health Science Center

ICH Day	ICH	
Educational Workshop		
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operation and Quality Management		
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines	Ø	
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

Session 0703 | December 10, 2022

13:30–15:00 Regulatory Compliance in Drug Safety

#### SESSION CHAIR Xiaojing ZHAN Vice President, Drug Safety, Junshi

Since China officially became a member of THE ICH in 2017, the Chinese drug regulatory authority has issued a series of new regulations and updated requirements on the basis of the original, and gradually carried out closer alignment with the international general technical standards and guidelines. The pharmaceutical administration law of the People's Republic of China, the pharmaceutical marketing authorisation holder (MAH) for the announcement of adverse reactions, the example of adverse drug reactions of collection and reporting guidelines circular pharmacovigilance quality management specification and other documents in the further clear the drug marketing authorisation holder (MAH) and bidders pharmacovigilance activities actively, Obligations and standards to minimize drug safety risks, protect and promote public health. 202204 The state promulgated the new Guiding Principles for Pharmacovigilance Inspection, which provides further guidance for urging holders to further improve the pharmacovigilance system, standardize the development of pharmacovigilance activities, ensure the continuous compliance with the requirements of laws and regulations, and effectively fulfill the responsibilities of pharmacovigilance subjects.

This conference will summarize and share working practices from the perspective of MAH and research center to see how to carry out pharmacovigilance work, how to effectively manage third parties, and discuss common findings in compliance inspections.

**PSMF** Practical Consideration

**Lynn ZHOU** PV Head, Sanofi

#### Vendor Management of PV

**Cindy LIN** Senior PV Manager, China Guangzhou Junxin Pharmaceutical Co., Ltd. (CSL Behring China Affiliate)

### Pharmacovigilance Compliance from an Institutional Perspective Ye CAO

Deputy director of clinical Research Department/Drug Clinical Trial Institution Office of Cancer Hospital affiliated to Sun Yat-sen University'

#### Common Finds in PV Inspection

Conny MO

Founder, Medical Safety Advisor, Beijing XAJK Medical Technology, Co., Ltd.

ICH Day	ІСН
Educational Workshop	
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0704 | December 10, 2022

16:00–17:30 Drug Safety in Therapeutic Areas

SESSION CO-CHAIRS Howe LI, MD, PhD Chairman and CEO, Deltamed Co. Ltd

Zheng JIAO Director of Pharmacy Department, Deputy Director of GCP Center, Chest Hospital Affiliated to Shanghai Jiaotong University

Risk Consideration in FIH Study Wei LI, MD, PhD Director of Oncology Center Phase I, Pulmonary Hospital

Safety in the Development of Innovative Drugs for Mental Diseases Huafang LI Professor, Director of Clinical Research Center, Shanghai Mental Health Center

Safety Risk Discovery and Evaluation of Roxadustat Guangiao LI, PhD Assistant Professor, Vanke School of Public Health and Wellness, Tsinghua University

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operatio and Quality Management	ns 🔏
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	<b>NO</b>
Hot Topics	

Session 0705 | December 11, 2022

08:30-10:00 COVID-19 Drug Safety

#### SESSION CHAIR

Yuan MENG Head of Medical Office R&D, I-Mab Biopharma

COVID-19 Vaccine Specific Safety Monitoring Requirement and Methodology Yan CHEN Vice President, Global Drug Safety, Pfizer

Drug Safety in Intensive Care for COVID-19 Xinyu WANG Deputy Chief Physician, Dept. of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University

Emergency use of the Vaccine Safety Platform Barbara LAW Team Member, Safety Platform for Emergency vACcines

ICH Day	ІСН
Educational Workshop	$\bigcirc$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 0706 | December 11, 2022

#### 10:30–12:00 PV Meets Information Technology and Methodology

#### SESSION CHAIR Conny MO Founder, Medical Safety Advisor, Beijing XAJK Medical Technology, Co., Ltd.

When IT meets with Pharmacovigilance, what it means – effectiveness improvement, high-quality data, process automation of PV operation as well as signal detection in real world safety data bring us much more breakthroughs and possibilities?

The integration and development of pharmacovigilance and information technology achieves the life cycle risk management of Pharmacovigilance and ultimately contribute to patient safety.

Robotic Processing Automation RPA in Use of Pharmacovigilance Operation William WAN Taimei

#### Interactive Visualization Tools for Clinical Aggregated Data Assessment Co-presenters

Mengchun Ll PV Director, TB Alliance

Xiao NI Senior Director, Biostatistics, Sarepta Therapeutics

### Integrating Pharmacometric Modelling into Pharmacoepidemiological Research Using Real World Safety Data Zheng JIAO

Director of Pharmacy Department, Deputy Director of GCP Center Chest Hospital Affiliated to Shanghai Jiaotong University

#### Approach of Multi-factor Analysis in Signal Detection

Conny MO Founder, Medical Safety Advisor, Beijing XAJK Medical Technology, Co., Ltd.

ICH Day	СМС		
Educational Workshop	THEME LEAD Steven HU, P	hD	Lily XIONG
Opening Plenary		I Officer, Everest Medicine	Executive Dir
Global Regulatory Townhall	Xiaoping CAO SVP, Head of T	echnology Operations, JW Therapeutics	Na XU RA Director,
China Regulatory	Session 0801 8	0802   D <mark>ecember 10, 202</mark> 2	
Special Session	8:30-12:00	Regulatory Science in Gene and Cell Thera	py - Part I and Part II
Regulatory Science		SESSION CO-CHAIRS Irene DENG	
Drug Clinical		Regulatory Affairs Head, Sanofi	
Development		Renhua KOU Senior RA Director, BeiGene	
and Quality Management		Cell and Gene Therapy Products Regulatory Clir	nical Considerations and Te
Clinical Needs and Trial Platform		CDE Speaker Invited Cell and Gene Therapy products Supervised Site	e Verification and Inspectio
Data Science		CFDI Speaker Invited	
Biostatistics		EMA's Considerations and Prospects for the Reg <b>Patrick CELIS</b> EMA	gulation of Cell and Gene T
PV & Drug Safety		FDA Considerations and Prospects for Regulatic <b>Guang GAO, PhD</b> Senior Technology Officer, PATH	on of Cell and Gene Therap
смс		Cell and Gene Product Development Status and	Case Sharing
Translational Medicines		<b>Chunlin ZHAO</b> Founding Partner of Anlong Fund and Founder	of Anlong Biotech
		Panel Discussion	
Non-clinical & Animal Test	<b>)</b>		
Medical Writing and Publication			
Pediatric Drug Development Forum			
Hot Topics			

Lily XIONG Executive Director, CMC, BeiGene

Na XU RA Director, 3DMed

tory Clinical Considerations and Technical Review Requirements

ised Site Verification and Inspection Requirements

the Regulation of Cell and Gene Therapy Products

legulation of Cell and Gene Therapy Products

CH Day	СМС		
Educational Workshop	Session 0803	December 10, 2022	
Opening Plenary	13:30-15:00	CMC Development for Advanced Therapies & Technologies of Biologics	
obal Regulatory wnhall		SESSION CHAIR Steven HU, PhD Chief Technical Officer, Everest Medicine	
egulatory Session		ADCs: Past, Present and Future Speaker Invited	
ry Science		Topic TBD Jimmy LI, PhD Senior Vice President, WuXi Biologics	
al 🔬		Topic TBD Jiaqiang CAI	
d Clinical Operations		CSO, MediLink Therapeutics	
eeds and	Session 0804		
	16:00-17:30	CMC Regulation and Challenges of mRNA and Cell Therapy	
		SESSION CO-CHAIRS Xiaoping CAO, PhD SVP, Head of Technology Operations, JW Therapeutics	
		Na XU	
$\langle \cdot \rangle$		RA Director, 3DMed	
		CMC Development and Challenges of Cell Therapy <b>Shuyuan YAO, PhD</b> CEO of Hillhouse	
I Medicines		CMC Regulatory Consideration for Cell Therapy Products <b>Cheng YIN, PhD</b> Head of Process Development, JW Therapeutics	
Animal Test		From Technology to Medicine: Mobius Ring for Autologous Somatic Therapy of CMC	
riting and		<b>Xin'an LU, PhD</b> CMO, Imuno Pharma	
ug ht Forum			
pics			2022 DIA China Annual Meeting 78

ICH Day	ІСН
Educational Workshop	$\overline{\bigcirc}$
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operatio and Quality Management	ns 🔼
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	ר
Hot Topics	

## СМС

Session 0805 | December 11, 2022

8:30-10:00 CMC Regulatory Requirements - Small Molecules Drug

#### SESSION CHAIR

Lily XIANG Executive Director, CMC, BeiGene

The wave of innovation development of medicine, Chinese medicine enterprises in the face of China's regulations, to declare at the same time considering filing stage to go global, in pharmaceutical development and formation of CMC technical documents to declare to be proactive when implanted all regulatory requirements, in the limited resources, time and manpower cost under the premise of must also ensure that declare success rate. Therefore, how to coordinate the different technical requirements of various countries and optimize the priority order of declaration according to the time node of CMC development has become the top priority of each pharmaceutical enterprise.

In addition, as China became a member of the, for example, in the past six years in a more open mind incorporates more pharmaceutical related ICH guidelines, we are delighted to see China CDE review requirements and standards also adjusted to a certain extent, and CDE in China's own hard-working guidelines, drug companies colleagues at the same time of learning rules, We also need to learn from each other, and this DIA Annual Conference will strive to provide more opportunities for everyone to share and learn.

CMC Regulatory Requirements for Sino-US NDA Application of Chemical Innovation Drugs Youxuan LI Registered Director of Pharmaceutical Sciences, China and Asia Pacific region, BeiGene

#### CMC Requirements for Pediatric Drug in US

Yang WANG Senior Registration Director, Innocare Pharma

#### Development and Difficulties of CMC Registration Requirements in China under Global Synchronous Development

**Zhengyu WU** Director of Registration, NovoNordisk

### Control Strategy Development for New Chemical Entities Joerg SCHIEWE

Head of Global CMC Expert NCE, Boehringer Ingelheim

#### Panel Discussion

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	Ø
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

### SESSION CHAIR Jun LU, PhD CMC Head, Boehringer Ingelheim Regulatory Considerations on CMC for Application of Innovative Biologic Drugs in China and the United States Chenshu LU RA Director, BeiGene Pharmaceutical Technical Requirements and Challenges for Global Application of Innovative Biologics Wei LI Deputy Director of registration Affairs Department of Wuxi Pharm Biotechnology Co., LTD.

CMC Regulatory Requirements - Biologic Drug

CMC

10:30-12:00

Session 0806 | December 11, 2022

Characteristics and Key points of WRITING CMC Application Materials for ADC Drugs Xiaoning LI Deputy Director, Registration, RemeGen

#### Panel Discussion Invited Panelists

**Baoquan LI** Registration, Innovent

Juhong LIU, PhD Chief Scientific Officer, EVIVE Biotech

ICH Day	<b>Transla</b>	tional Medicines		
Educational Workshop	THEME LEAD Xinying SU, M	ID, PhD Yi ZHENG, PhD		
Opening Plenary		Translational Medicine and Diagnostic Lead, Head of Translational Science Center, JnJ		
Global Regulatory Townhall	Session 0903	December 10, 2022		
China Regulatory	13:30-15:00	What Does Translational Medicine Really Mean?		
Special Session Regulatory Science		SESSION CHAIR Yi ZHENG, PhD Head of Translational Science Center, JnJ		
Drug Clinical Development	Ð	Translational Medicine - from T0 to T4 <b>Xinying SU, MD, PhD</b> Senior Director, Translational Medicine and Diagnostic Lead, Development China, Pfizer		
Patient Centered Clinical Operations		Translational Medicine - Perspective from Investigator Jianming YIN		
Clinical Needs and Trial Platform		Head of Pathology Department, CICAMS		
Data Science		Translational Medicine - Perspective from Industry <b>Tianyuan ZHOU, PhD</b> Head of Translational Medicine China, AZ		
Biostatistics	Session 0904	December 10, 2022		
PV & Drug Safety	16:00-17:30	Application of Translational Medicine: Innovations		
смс		SESSION CHAIR Xinying SU, MD, PhD Senior Director, Translational Medicine and Diagnostic Lead, Development China, Pfizer		
Translational Medicines		Gold Digger: Advanced Analytic Methodology Application in Translational Research <b>Xinyi YANG, PhD</b> Senior Scientist, AP CoE in Translational Science, Janssen AP R&D		
Non-clinical & Animal Test		Translation from Real World Data Intelligence to Novel Drug R&D Qiang XU, PhD		
Medical Writing and		President & CEO, Geno Micare Bio		
Pediatric Drug Development Forum	<b>)</b>	Therapeutic Target and Efficacy Prediction in Precision Medicine for Treating Lung Cancer <b>Xuchao ZHANG</b> Associate Director, Guangdong Institute of Lung Cancer		
Hot Topics			2022 DIA China Annual Meeting	81

Day ICH	Indiisid	ational Medicines	
ucational Workshop		December 11, 2022	
pening Plenary	8:30-10:00	Regulation Update on Translational Medicine	
obal Regulatory 👔		SESSION CHAIR Sharon CAI Senior Regulatory Affairs Director, Roche Diagnostics Shanghai Ltd.	
ina Regulatory ecial Session		Two New Guidance on Co-developed & follow-on Companion Diagnostic Products CMDE Speaker Invited	
gulatory Science		Collaboration Model & Opportunities between Pharma & CDx company Annie YIN VP, Medical Regulatory Affairs, Roche	
ug Clinical evelopment		Worldwide Simultaneous Development of Innovative Drugs and Companion Diagnostics <b>Zhirong SHEN</b> VP, Head of Translational Discovery, Research & Medicine, BeiGene	
nical Needs and	Session 0906		
	10:30-12:00	Exploring Collaboration Models in Translational Medicine	
ata Science		SESSION CHAIR Xu HUANG Associate Director, AP CoE in Translational Science, Janssen AP R&D	
' & Drug Safety		Construction and Development of Clinical Biological Sample Resource Network in Beijing Lei ZHANG General Manager of Biotechnology Research Institute of Beijing Life Science Park Co., LTD	
1C 主		Research Hospital Enable Translational Medicine <b>Shuhang WANG, MD</b> Cancer Hospital, Chinese Academy of Medical Sciences	
anslational Medicines		Panel Discussion	
on-clinical & Animal Test	) —	Above Speakers and Invited Panelists	
edical Writing and Iblication			
ediatric Drug evelopment Forum			
ot Topics			2022 DIA China Annual Meeting

MAN

		0		
ICH Day	Non-cli	inical & Animal Test		
Educational Workshop	THEME LEAD Jack XIE, PhD		Yi JIN, PhD	
Opening Plenary		cal Sciences and Translational Safety, Janssen R&D		t and Regulatory Affairs, WuXi Appec Suzhou
Global Regulatory	Xiantang LI, P Senior Director,	hD Non-clinical Drug Safety, Pfizer		
China Regulatory Special Session	to early clinical	nal pharmaceutical companies in China try to move Pi studies; Local companies are also increasingly looking eed to learn more about non-clinical knowledge expa	to do the real innovation needed for toxic	ology research
Regulatory Science	The sessions ho	ped to attract more clinical and regulatory profession	als through the well designed content and	sharing their interests of the topics.
	Session 1001	December 10, 2022		
g Clinical elopment	08:30-10:00	Nonclinical Data to Support Clinical Develop	ment	
: Centered Clinical Operations		SESSION CO-CHAIRS CDE Session Chair Invited		
cal Needs and Platform		Jack XIE, PhD Head of Preclinical Sciences and Translational Safe	ty, Janssen R&D	
Science		Clinical Translation of Nonclinical Drug Safety Asse Nasir Khan, PhD	essment	
tistics		Chief Non-clinical Safety Officer, Drug Safety Rese	arch & Development, Pfizer	
Safety		Integration of Preclinical Information to Effective C Jia JI JnJ	linical Dosing Strategy	
		Nonclinical Animal Models: Recent Progresses and Chuan QIN, PhD	Clinical Translation	
tional Medicines		Dean, Chinese Academy of Med. Science		
clinical & Animal Test				
dical Writing and Dication				
ediatric Drug evelopment Forum				
ot Topics				2022 DIA China Annual Meeting 83

#### 2022 DIA China Annual Meeting 83

ICH Day	ICH
Educational Workshop	
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

### **Non-clinical & Animal Test**

Session 1002 | December 10, 2022

### 10:30-12:00 Nonclinical Assessment of New Modalities

SESSION CO-CHAIRS Yi JIN, PhD VP and Head of Program Management and Regulatory Affairs, WuXi Appec Suzhou

Chuan QIN, PhD Dean, Chinese Academy of Med. Science

Nonclinical Safety Assessment Strategy for Oncolytic virus Therapeutics Xuedong DAI, PhD Vice President of Beijing Saifu Pharmaceutical Research Institute Co., LTD

Nonclinical Safety Assessment Strategy for Oligonucleotide Therapeutics Yan CHANG, PhD General Manager, InnoStar

Nonclinical Safety Assessment Strategy for Monoclonal Antibody Therapeutics Xiaobo CENG, PhD CEO, West China-Frontier PharmaTech

Nonclinical Safety Assessment Strategy for Antibody Drug Conjugate (ADC) Therapeutics Yi JIN, PhD VP and Head of Program Management and Regulatory Affairs, WuXi Appec Suzhou

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	$\bigcirc$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

# **Medical Writing and Publication**

#### THEME LEAD Nan WANG, PhD

Senior Director, Medical Writing Services Asia-Pacific, Parexel China Co., Ltd.

#### Session 1101 | December 10, 2022

#### 08:30-10:00 Value of Medical Writing in the Pharmaceutical Industry

#### SESSION CHAIR Ning ZHENG, PhD

Director, Head of Medical Communication, AstraZeneca R&D China

Medical writing as a profession is booming in recent years in China, with a fast-growing number of medical writers and an even fastergrowing demand from pharmaceutical companies, biotech firms, and CROs, while providing high quality submission package within timeline is a crucial step in the drug development process.

In this session, we will discuss the value medical writers could bring to the clinical submission team and how medical writing expertise can help in the communication with health authorities. In light of this, we will continue to discuss the career journey for a medical writer to develop the skillsets, build the competency, and demonstrate the value.

#### The Value of Medical Writing: AMWA Survey and China Status CO-PRESENTERS Julia COOPER, PhD, FRSC

Corporate Vice President, Head of Global Medical Writing Services, Parexel International Ltd

#### Xiaoling WANG

Head of Clinical Documentation China team, Clinical Science Operation, Sanofi R&D China

#### The Core Competency of a Medical Writer (MW)\_Beyond Medical Writing

Lynnette LIN, PhD Principle Medical Communication Scientist, Medical Communication, AstraZeneca R&D China

#### Panel Discussion

INVITED PANELISTS Lei QIAN, MD, PhD

Vice President, Clinical Development, Innoventbio

#### Eric ZHANG, PhD

Vice President, Head of Data Science, Rundong Pharmaceutical

#### Marilyn LIU

RA Head, Rare Products & Diabetes & Excellence, Regulatory Affairs, Sanofi China Corporate

ICH Day	ICH
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

## **Medical Writing and Publication**

#### Session 1102 | December 10, 2022

10:30-12:00 The Value of Medical Writing in Clinical Document Preparation for NDA/BLA Submissions

#### SESSION CHAIR

Helen WANG, PhD Medical Writing Team lead, China Clinical Documentation, Sanofi

The importance of high-quality submission documents for a successful NDA/BLA cannot be overemphasized. Since the implementation of ICH guidelines in China, preparation of clinical documents in accordance with regulatory specifications within limited timeframes has put forward higher requirements and greater challenges for document development teams, highlighting the indispensable value of medical writing in this process.

In this session, industry experts will be invited to share from a medical writing perspective on how to author clinical documents with the health authority reviewing in mind, how to accelerate submission timelines through strategic planning and messaging, and how to efficiently coordinate the document preparation process, based on their rich experiences from various global and China NDA/BLA submissions.

#### Writing as a Content Strategist Wei GONG China RDT Lead, Roche (China) Holding Ltd

Clinical Overview Writing: How to Complete a Structured Benefit-risk Section with Health Authority Reviewers in Mind Yingjie ZHAO Senior Regulatory Writer, Global Drug Development (China), Novartis AG

### How to Act as a Lead Medical Writer to Accelerate NDA/BLA Submission Dossier Preparation Changhui MAO, PhD

Medical Writing Lead, Janssen China R&D Center, Johnson & Johnson (China) Investment Ltd.

#### Panel Discussion

INVITED PANELISTS Yuxiao LIU Medical Writing Associate Director, BeiGene

Jing JIE Senior Manager, Medical Writing, Takeda Development Center Asia

Yiting LIU, PhD Medical Writing Team Lead, Pfizer China Research & Development Center

ICH Day		ICH		P
Educational W	/orkshop	<b>()</b>	S	Se
Opening Plena	ary		8	3:3
Global Regula Townhall	tory			
China Regula Special Sessi				
Regulatory Sc	ience			
Drug Clinical Development				
Patient Centered Cl and Quality Manage				
Clinical Needs Trial Platform	and			
Data Science				
Biostatistics				
PV & Drug Saf	ety			
СМС				
Translational	Medicines			
Non-clinical & A	nimal Test			
Medical Writir Publication	ng and			
Pediatric Drug Development				
Hot Topics				

## Pediatric Drug Development Forum

ession 1201 | December 10, 2022

 30-10:00
 Pediatric Drug Development – Part 1: Pediatric Clinical Trials and Regulatory Consideration

 SESSION CHAIR
 Ao PENG, PhD

 Head, Clinical Pharmacology and Early Clinical Development, Pfizer

 CDE Pediatric Guideline Interpretation

 China CDE Speaker Invited

 Current Clinical Trial Status of China Pediatric Drug – Physician Perspective

 Jinhu WANG, PhD

 Deputy Director of Hematological Tumor Center, Children's Hospital affiliated to Zhejiang University School of Medicine

 Pediatric Drug PK/PD

 Jing LIU, PhD

 Senior Director, Clinical Pharmacology, Pfizer

ICH Day	ІСН
Educational Workshop	Ō
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

# Pediatric Drug Development Forum

#### Session 1202 | December 10, 2022

10:30-12:00

SESSION CHAIR	
Wei ZHAO, PhD	
Professor, Clinical Pharmacy	School of Pharmacy, Shandong University
CDE Guidelines for Extrapole CDE Speaker Invited	on Adult Medication Data to the Pediatric Population
Use of Adult Extrapolation in Jing ZHANG, MD, PhD	Pediatric Drug Development - Case Sharing
,	logy, Deputy Director, Institute of Antibiotics, Huashan Hospital, Fudan University
The Use of Extrapolation in I	diatric Drug Development
Robert Nelson, MD, PhD	
Senior Director, Pediatric Dr	Development (CHILD) Johnson & Johnson, United States

ICH Day	ІСН
Educational Workshop	<b>(</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	Ø
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

## Pediatric Drug Development Forum

#### Session 1203 | December 10, 2022

13:30-15:00

SESSION CHAIR Jianing DI, PhD Senior Director, China Compound Team Leader, Janssen China R&D

Pediatric Drug Development - Part 3: RWD & Panel Discussion

Considerations Related to Dosing Determination of the Licensed Drug Product, Dastuximab  $\beta$  Injection **Zou JUN** Hainan Women and Children's Medical Center

From Design to Real World Application Vega Masignani GSK

Panel Discussion INVITED PANELISTS CDE Panelist Invited

Ling HUANG Hainan CDE

Jinhu WANG, PhD Deputy Director of Hematological Tumor Center, Children's Hospital affiliated to Zhejiang University School of Medicine

Wei ZHAO, PhD Professor, Clinical Pharmacy, School of Pharmacy, Shandong University

**Zhizhong LI, PhD** Secretary General, Shiyu Children Foundation

Yongjing ZHANG, PhD Senior Director, Asia Pacific Epidemiology Division, Johnson & Johnson

ICH Day	ICH	
Educational Workshop	0	
Opening Plenary		
Global Regulatory Townhall		
China Regulatory Special Session		
Regulatory Science		
Drug Clinical Development		
Patient Centered Clinical Operation and Quality Management	s A	
Clinical Needs and Trial Platform		
Data Science		
Biostatistics		
PV & Drug Safety		
СМС		
Translational Medicines		
Non-clinical & Animal Test		
Medical Writing and Publication		
Pediatric Drug Development Forum		
Hot Topics		

Session 1301 | December 10, 2022

8:30–10:00 Market Access in Drug Development

#### SESSION CO-CHAIRS

#### Yi CHEN, PhD

Professor and Researcher, Institute of Hospital Management, Tsinghua University Co-head of Biomedical Innovation Center, Shanghai Chuangqi Health Development Institute

#### Dajun YANG, PhD

Chairman of the Board, Executive Director and CEO, Ascentage Pharma

In the pharmaceutical market environment of China, the medical insurance market occupies an absolutely dominant position, and all kinds of pharmaceutical companies set the core strategy and access goal of entering the medical insurance market quickly after the product is approved. The national medical insurance catalogue has been updated for five consecutive years, entering a "new normal" of dynamic adjustment. In 2021, the National Medical Insurance Administration will require applicants to submit evidence information on five value dimensions, including effectiveness, safety, economy, innovation and fairness. For economic evidence, such as Cost Effective Analysis, pharmacoeconomic experts collect real world data to conduct pharmacoeconomic evaluation after the product is launched, which takes a long time and costs a lot. How to advance pharmacoeconomic evaluation to the clinical trial stage of drug development, collect the data required by pharmacoeconomics while collecting drug safety and efficacy, and provide supporting evidence for market access? How do pharmaceutical companies synchronously formulate new drug registration strategy and market access strategy?

### The Importance of Taking Market Access Strategies into Consideration during the Clinical Trial Phase of Drug Development Dajun YANG, PhD

Chairman of the Board, Executive Director and CEO, Ascentage Pharma

#### New Normal of Drug Registration and Approval and Medical Insurance Access Yi SHAO

Executive Director, McKinsey

### Implications of China's Medical Insurance Payment Environment for New Drug R&D Yi CHEN, PhD

Professor and Researcher, Institute of Hospital Management, Tsinghua University Co-head of Biomedical Innovation Center, Shanghai Chuangqi Health Development Institute

#### Panel Discussion

ICH Day	ІСН
Educational Workshop	<b>()</b>
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operation and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

Session 1302 | December 10, 2022

10:30–12:00 eSource Data: Opportunities and Challenges for Improving Data Acquisition Efficiency

#### SESSION CHAIR

Charles YAN, PhD Vice President, Data Science Center, Hengrui

The atmosphere was tense at the DIA 2021 Annual Meeting, based on differing perspectives from speakers at eSource Session. After the meeting we all made a deep analysis and reflection, to discuss the reasons of differences, such basic agreement, namely the electronic source data is the core of clinical research is the most important assets, but because of the ownership of the data, use right and the right to know is not yet clear and normative problem has not been thoroughly solved, the electronic data acquisition must be a serious problem. This session will continue this theme, hoping that we can gradually improve the understanding of the debate, reach consensus, and guide the practice to make electronic data better used in clinical research.

#### Electronic Source Data: Current Difficulties and Challenges Zhenglong TIAN Vice President and Chief Data Officer, Gobroad Hospital Management Co., LTD

Current Situation and Future Direction of Centralized Electronic Data Collection Yanfei LIU

Director of GCP, Fudan University Cancer Hospital

#### Panel Discussion

Above Speakers and Invited Panelists Yue ZHANG General Manager, Data Science Center, Clinical Product Development Department, Shanghai Henlius Biotechnology Co., LTD

### Xin CHEN

Senior Manager, Hengrui Medical Data Science Center

#### Feng SHENG

Vice President of Business Development, Asia Pacific, Viedoc Information Technology Co., LTD

ICH Day	ІСН
Educational Workshop	ð
Opening Plenary	
Global Regulatory Townhall	$( \mathbf{G} )$
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	
СМС	
Translational Medicines	Ø
Non-clinical & Animal Test	
Medical Writing and Publication	Ê
Pediatric Drug Development Forum	
Hot Topics	

16:00-17:30

Session 1304 | December 10, 2022

Building a Portfolio for Global: Where We Are & Where to Focus SESSION CO-CHAIRS

Huading ZHANG Chief Operating Officer, Alebund Inc.

Yang SONG Head of China PMO, Janssen R&D

Chinese Biopharmaceutical Enterprises Go Global Helen Chen Managing Partner, L.E.K. Consulting

Strategy and Consideration of Product Pipeline of Chinese Biotech Joan Shen CEO, Neushen

Panel Discussion Invited Panelists **Cyber Cao** Managing Director, Sequoia Capital

Feng Bian Executive Director of Integrative Sciences, China R&D, BMS

Yinxiang Wang Chairman & CEO, Jacobio Pharma

ICH Day	ICH
Educational Workshop	
Opening Plenary	
Global Regulatory Townhall	
China Regulatory Special Session	
Regulatory Science	
Drug Clinical Development	
Patient Centered Clinical Operations and Quality Management	
Clinical Needs and Trial Platform	
Data Science	
Biostatistics	
PV & Drug Safety	$\bigcirc$
СМС	
Translational Medicines	
Non-clinical & Animal Test	
Medical Writing and Publication	
Pediatric Drug Development Forum	
Hot Topics	

8:30-10:00

Session 1305 | December 11, 2022 **Agility in Clinical Project Management** SESSION CO-CHAIRS **Tina TIAN** Kevin LI Head of PM, Roche China Development Center VP, Clinical Operation, Everest Medicines Under the fast changing drug development environment with fierce competitions, integrate Agile PM methodology into 'innovation through collaboration' would be quite fundamental to our future success. We need to fully leverage the advantages of developed assets, dynamic regulations and unmet medical needs through continuous iteration and deconvolution, to ensure sustainable drug development success, tailored health care solutions to patients as well as leading the future with agile innovations. Why-What-How about Agility Management Karen XU Founder, Timesct Regulatory Agility in Ages of COVID-19 Handsome JI Regional Publishing Lead, Asia, Pfizer Agile and Sustainable Clinical Supply Chain and Manufacturing Strategy Vivian JIA AD, Supply Chain Management, CMC, Everest Medicines Panel Discussion

	ICH Day	ІСН	Hot To	pics		
Educational Workshop		<b>()</b>		Session 1306   December 11, 2022		
	Opening Plenary		10:30-12:00	Innovation & G		
	Global Regulatory Townhall			Under the policy important link in quality of clinica		
	China Regulatory Special Session			and the safety of during clinical re How to conduct		
	Regulatory Science			of concern in the capacity of biote system, etc., bec		
	Drug Clinical Development			This session will sample preparat		
	Patient Centered Clinical Operatio and Quality Management	ns 🔏		biotechnology d the international		
	Clinical Needs and Trial Platform			FDA Biological P Jonathan CHA Medical Product		
	Data Science			Considerations for		
	Biostatistics			Lixin WANG Deputy Director,		
	PV & Drug Safety			Scientific Consid Biotechnology D <b>Zhengyu WU</b> RA Director, AZ		
	СМС	÷		Panel Discussion		
	Translational Medicines			Invited Panelist <b>Dongming WA</b> Senior Vice Presi		
	Non-clinical & Animal Test					
	Medical Writing and Publication	Ê				
	Pediatric Drug Development Forum					
_	Hot Topics					

**Innovation & GMP Compliance - Yeehong Joint Session** 

the internationalization of biotechnology drugs.

Medical Product Supervisor, FDA China Office

Senior Vice President, Quality, Innovent Bio

FDA Biological Product Inspection

Jonathan CHAPMAN

**Biotechnology Drugs** Zhengyu WU RA Director. AZ

Panel Discussion Invited Panelist Dongming WANG

Under the policy environment of encouraging drug innovation, China's innovative drug research is in full swing. Clinical research is an important link in the research and development of innovative drugs. The guality of clinical trial samples is one of the key factors affecting the quality of clinical trials. The quality control of the preparation of clinical trial samples is very important to ensure the quality of clinical trials. and the safety of subjects. Based on the gradual and uncertain characteristics of innovative drug development, the production site change during clinical research of innovative biotechnology drugs is inevitable and in line with the law of innovative research and development. How to conduct a comparable study on the production site change during clinical research based on risk and science is a scientific issue of concern in the industry. In addition, due to the complexity and particularity of biological macromolecules, the commercial production capacity of biotechnology drugs, the quality management and risk control ability, the implementation of GMP management concept and

This session will discuss the key points of FDA biologic drug inspection and regulation from multiple perspectives, the quality control of sample preparation for clinical trials in China, as well as the risk assessment of production site change during the clinical period of innovative biotechnology drugs and the scientific consideration of comparability research, so as to facilitate the development of innovative drugs and

Considerations for Quality Control of Investigational Medicinal Products - An Understanding of the Contents of the GMP Appendix

Scientific Considerations for Risk Assessment and Comparability of Manufacturing Site Changes During Clinical Trials of Innovative

system, etc., become the bottleneck of whether the biological drug enterprises can grow bigger and stronger.

Deputy Director, Certification and Evaluation Center of Jiangsu Drug Administration